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III Abstract 
Microglia, the resident immune cells of the central nervous system (CNS), are 
responsible for tissue homeostasis and host defense. After activation, they can 
also be involved in a wide range of neurodegenerative diseases including 
amyotrophic lateral sclerosis (ALS). In ~10 % of the hereditary ALS cases, the 
disease is caused by a mutation in the superoxide dismutase 1 (SOD1) gene. The 
exact pathophysiological role of mutant SOD1 in human microglia is still unclear.  
Microglial precursors were generated from human induced pluripotent stem (iPS) 
cells to a proliferating cell line to overcome the limitations of primary microglia. The 
obtained iPS-derived microglial precursor (iPSdM) cells were positively stained for 
Iba1 and CD68, markers widely expressed on microglia. Moreover, flow cytometry 
analysis demonstrated the expression of typical microglial markers like CD11b, 
CD45, CD49d, CD86, CD206 and CX3CR1 whereas the cells were negative for 
the hematopoietic stem cell marker CD34. Functional analysis revealed the 
capability of beads and fibrillary amyloid β phagocytosis. Furthermore, iPSdM 
showed upregulation of tumor necrosis factor α (TNFα) gene transcription after 
lipopolysaccharide (LPS) stimulation and chemokine-directed migration towards 
CX3CL1. Transplantation of iPSdM into the hippocampus of immunodeficient mice 
showed the capability of these cells to migrate and integrate into the brain 
parenchyma. 
Next, iPSdM were genetically engineered to express distinct human mutant SOD1 
to model SOD1-mediated ALS. Mutant SOD1 expressing iPSdM showed no 
differences in cytokine production or alterations in mitochondrial enzymes in 
comparison to SOD1 wildtype expressing cells. In contrast, iPSdM expressing 
SOD1-G37R or SOD1-G93A showed increased induced superoxide production 
after stimulation with TNFα, LPS or interferon γ, respectively.  
Thus, data demonstrate the generation of human microglial precursor cell lines 
from iPS cells and their application as neuroinflammatory disease model for 
mutant SOD1-mediated ALS. 
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1 Introduction 
1.1 Microglia 
1.1.1 Microglia in the CNS 
The central nervous system (CNS) consists of two main cell types: neurons and 
glial cells. Neurons build a network throughout the nervous system and transmit 
information through electrical conduction. Glial cells play a supportive and 
protective role to neurons and are not directly involved in the conduction process. 
Glial cells can be subdivided into two main classes: macroglia consisting of 
astrocytes and oligodendrocytes and microglia.  
Microglia are the resident immune cells of the CNS and constitute about 10 % of 
all brain cells (Ransohoff and Perry, 2009). Ramon Y Cajal defined them as the 
third group of CNS cells termed mesoglia (Rezaie and Male, 2002). Del Rio-
Hortega was the first defining the term microglia and proposed that they can 
change their morphology dependent on the activation stage (del Rio-Hortega, 
1933). Microglia are distributed throughout the whole brain parenchyma but are 
predominant in the grey matter with highest concentration in the hippocampus, 
substantia nigra, olfactory telencephalon and basal ganglia (Block et al., 2007). 
Microglia are mainly involved in tissue homeostasis by scavenging invading 
microorganisms and apoptotic cells and furthermore act as immune effector cells 
(Kettenmann et al., 2011). 
 
1.1.2 Origin of Microglia 
Nowadays it is suggested that microglia populate the brain in two waves. In mice, 
microglia first colonize the brain during embryonic development around embryonic 
day (E) 8.5-10 in the neuroepithelium (Alliot et al., 1999). The second wave occurs 
in the brain during fetal development from E13.5 until birth (Chan et al., 2007). 
Some authors suggested the yolk sac as the tissue of origin (Alliot et al., 1999, 
Kaur et al., 2001). Alliot and colleagues (1999) reported that cells with properties 
of microglial precursors can be first detected at embryonic day E8 in mice and that 
most of these progenitors originate from the yolk sac. A recent publication clearly 
showed that microglial cells develop in the yolk sac from immature macrophages 
before day E8 (Ginhaux et al., 2010). These cells migrate into the CNS before 
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primitive or definite hematopoiesis occurs. Experiments demonstrated that 
microglia develop independently from cells arising in the bone marrow and 
peripheral myeloid cells do not contribute to maintenance of adult microglia 
(Ginhaux et al., 2010; Saijo and Glass, 2011).  
 
1.1.3 Functions of microglia 
In the healthy CNS, microglia are often termed as resting cells displaying a 
ramified morphology (Fig. 1.1) characterized by a small round cell body, 
extensively ramified processes and low expression of surface antigens (Garden 
and Möller, 2006). Processes of microglia directly contact astrocytes and neuronal 
cell bodies and continuously scan their environment. Time-lapse imaging using in 
vivo two-photon microscopy revealed that the somata of microglial cells remained 
fixed whereas the processes were remarkably motile undergoing withdrawal and 
new formation (Nimmerjahn et al., 2005). Resting microglia release immuno-
suppressant factors such as interleukin (IL)-10 and transforming growth factor β 
(TGFβ) as well as neurotrophic factors crucial for neuronal survival (Hanisch, 
2002; Ransohoff and Perry, 2009). Interaction of microglia with neurons seems to 
be important to keep them in a resting stage. In the healthy CNS, neurons 
suppress microglial activation through cell-cell contacts and secreted factors. For 
example, microglia are the only cell type expressing CX3 chemokine receptor 1 
(CX3CR1) in the CNS. Secretion of the ligand CX3 chemokine ligand 1 (CX3CL1) 
by neurons restrains microglial activation whereas interruption of this signaling 
resulted in increased neuronal death (Biber et al., 2007). 
 
 
Fig.1.1: Microglial cell in the mouse CNS. Highly ramified microglia stained with an antibody 
directed against ionized calcium binding adaptor molecule (Iba1). Scale bar: 20 µm. Modified from 
Soulet and Rivest, 2008. 
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In response to immunological stimuli or brain injuries, ramified microglia transform 
into activated cells (Fig. 1.2). Activation leads to an immediate microglial response 
resulting in migration to the lesion site, phagocytosis of apoptotic cells or debris, 
release of cytokines/chemokines and changes in the surface antigen profile. 
Furthermore, pro-inflammatory microglia release a wide range of soluble factors, 
dependent on the kind of stimulation, such as superoxide, nitric oxide (NO) and 
tumor necrosis factor α (TNFα) acting toxic against pathogens. Signals leading to 
activation include products of microorganisms, environmental toxins and protein 
aggregates (Hanisch, 2002; Zhou et al., 2005). In their activated state microglia 
upregulate several surface molecules such as CD14, major histocompatibility 
complex (MHC) molecules, complement receptors and chemokine receptors (Rock 
et al., 2004). Microglia express nine different toll like receptors (TLR 1-9) which are 
for example involved in detecting microbial infections like lipopolysaccharide 
(LPS), a component of gram-negative bacteria, lipoproteins, peptidoglycans and 
double-stranded RNA (Tsan and Gao, 2004; Garden and Möller, 2006). 
Furthermore, microglia upregulate metabotrophic P2 receptors to recognize 
signals from damaged cells like the nucleotides adenosintriphosphate (ATP) and 
uridintriphosphate (UTP; Napoli and Neumann, 2009). Upon immunological stimuli 
or in response to brain injuries microglia migrate along a chemokine gradient 
towards the stimuli (Cartier et al., 2005) and phagocytose dead cells and debris. 
The best studied “eat-me” signal coming from apoptotic cells is the phospholipid 
phosphatidylserine (PtdSer) which is normally located within the inner cell 
membrane. The location of PtdSer to the outer membrane as result of the 
apoptotic process serves as signal for recognition of these cells by phagocytes 
and their ingestion (Ravichandran, 2003).  
 
Fig.1.2: Morphology of microglia. Ramified microglia transform into an activated microglial cell 
(left to right). Modified from Kreutzberg, 1996. 
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1.1.4 Sources of microglia 
Microglial function is often studied on primary microglia from rodents. These cells 
can be isolated and enriched from mixed glial cultures by a shaking procedure 
(Giulian and Baker, 1986). Optionally, a pure population of microglial cells can be 
obtained using a combination of density gradients and flow cytometric sorting 
(Ford et al., 1995). This methodology was also applied to isolate human microglia 
post-mortem. Brain tissue from autopsy patients was used to isolate microglia by 
density gradient and magnetic-activated cell sorting (Olah et al., 2012; Melief et 
al., 2012). However, very limited numbers of primary microglia obtained from 
rodents and humans complicate classical biochemistry studies, systematic 
screening tests or cell therapy approaches. To circumvent these difficulties, mouse 
and human microglial lines were developed to substitute primary microglia. Murine 
cultured microglia were immortalized after infection with v-raf/v-myc recombinant 
retroviruses. The obtained BV2 cell line showed properties like macrophages in 
terms of antigen profile and phagocytic capacity (Blasi et al., 1990, Bocchini et al., 
1992). Later on, immortalized human microglial lines were developed by 
transfection of embryonic brain-derived macrophages with the SV40 virus (Janabi 
et al., 1995). Furthermore, the human microglial line HMO6 was generated 
through retroviral transformation of human embryonic telencephalon with v-myc 
(Nagai et al., 2001; Nagai et al., 2005). However, due to the transformation 
process these cells showed an altered cytokine profile and changes in their 
migratory capacity (Horvath et al., 2008, Napoli et al., 2009). Therefore, microglia 
derived from embryonic stem cells could provide a new tool to study microglial 
function in vitro and in vivo. 
 
1.2 Induced pluripotent stem cells 
Among stem cells, embryonic stem cells (ESC) have an enormous potential for 
biomedical approaches due to their capability of unlimited self-renewal and 
possibility to generate every cell type of an embryo. In 1998, the first human ESC 
line was generated by Thomson and colleagues (Thomson et al., 1998). Human 
ESC were isolated from the inner cell mass of an embryo from in vitro fertilization. 
Since 2001, more than 70 human ESC lines were already generated. 
Introduction 5 
Huge effort has gone into the development of functional equivalents of human 
ESC to overcome the ethical issue that a human embryo has to be destroyed. 
Takahashi and Yamanaka (2006) concentrated on the identification of pluripotency 
inducing factors. In 2006, they identified 24 candidates that were thought to be 
involved in maintaining pluripotency (Takahashi and Yamanaka, 2006). Using viral 
co-transduction of these factors, they generated the first cell lines with an 
embryonic-like state called induced pluripotent stem (iPS) cells. Further 
experiments demonstrated that overexpression of the four factors octamer 4 
(Oct4), SRY box-containing gene 2 (Sox2), Krüppel-like factor 4 (Klf4) and c-Myc 
is sufficient to reprogram murine fibroblasts. Using the same factors different 
groups succeeded in the generation of iPS cells from human adult fibroblasts 
(Takahashi et al., 2007, Yu et al., 2007). In general, iPS cells show similarities to 
ESC in terms of morphology, proliferation, teratoma formation and expression of 
pluripotency markers such as stage-specific embryonic antigen (SSEA)-3, 
SSEA-4, Tra1-60 and Tra1-81. Furthermore, iPS cells can be cultivated for 
extended periods and maintain a normal karyotype. In the absence of self-renewal 
factors, iPS cells differentiate spontaneously into embryoid bodies (EB) thus being 
able to build every somatic cell type of the organism. Teratoma formation is the 
gold standard test of pluripotency. IPS cells are injected into a tetraploid blastocyst 
and contribute to the generation of an entire living organism (Kang et al., 2009; 
Zhao et al., 2009). For human iPS cells, the system is conducted in mice showing 
a severe combined immunodeficiency (SCID) affecting both B- and T-
lymphocytes. Human iPS cells form teratomas comprising cells of all three germ 
layers (Takahashi et al., 2007, Yu et al., 2007). Immunohistochemistry analysis of 
cardiomyocytes confirmed the generation of the mesoderm whereas ectodermal 
and endodermal formation can be demonstrated using markers for neurons and 
pancreatic cells, respectively.  
Due to their potential to generate every somatic cell type, iPS cells could be a 
useful instrument in regenerative medicine especially when generated from 
patients. Recently, different groups succeeded in the generation of disease-
specific iPS cell lines from patients suffering from amyotrophic lateral sclerosis 
(Dimos et al.,2008), Parkinson’s disease (Soldner et al., 2009) and a variety of 
genetic diseases including Huntington’s disease (Park et al., 2008). Human iPS 
cells derived from patients can be used not only for drug screening but also to 
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investigate the pathology of the disease. Furthermore, the differentiation of iPS 
cells into the disease-affected cell type could be an approach for regenerative 
medicine. 
 
1.3 Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) is a late onset neurodegenerative disease with 
an incidence in Europe and Northern America of 1.9 per 100 000 population per 
year (Worms, 2001). Clinical symptoms include progressive muscular paralysis 
due to the degeneration of upper and lower motor neurons in the primitive motor 
cortex, brainstem and spinal cord, increased spasticity and hyper-reflexia 
(Rowland and Schneider, 2001; Glass et al., 2010). The median disease onset is 
with 55 years with a survival of 2-5 years after onset of symptoms. So far, ALS is 
fatal since no cure is available. Approximately 90 % of ALS cases are sporadic 
whereas 10 % are inherited (familial ALS). In sporadic and familial ALS the same 
neurons are affected thus they are indistinguishable by symptoms, but onset and 
duration of the disease vary (Boillee et al., 2006a).  
 
1.3.1 Role of superoxide dismutase 1 in ALS 
Dominant mutations in the gene encoding for superoxide dismutase 1 (SOD1) are 
the most common cause of familial ALS (Rosen et al., 1993). So far, more than 
114 mutations of SOD1 leading to ALS are known. SOD1 is a ubiquitously 
expressed homodimeric enzyme consisting of 153 amino acids with a stabilizing 
zinc ion and a catalytic copper ion in each subunit (Andersen, 2006). SOD1 
catalyzes the reduction of superoxide to hydrogen peroxide which is further 
reduced to water by glutathione peroxidase. Transgenic mice overexpressing 
mutated SOD1 (mSOD1) develop progressive motor neuron disease similar to 
symptoms observed in humans (Gurney et al., 1994; Wong et al., 1995; Bruijn et 
al., 1997). Thus, they can serve as animal models to study SOD1-mediated ALS. 
Toxicity of mSOD1 is non-cell autonomous. Mice expressing mSOD1 only in 
neurons (Pramatarova et al., 2001; Lino et al., 2002) or glial cells (Gong et al., 
2000) do not develop ALS.  
Experiments with mice clearly demonstrated that toxicity of mSOD1 is not due to a 
loss of enzyme activity as mice lacking SOD1 do not develop motor neuron 
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degeneration (Reaume et al., 1996). Furthermore, SOD1 toxicity is neither 
affected by reduced nor increased SOD1 wildtype activity (Bruijn et al., 1998; 
Jaarsma et al., 2001). Thus, mSOD1 has to cause disease through toxic 
properties. Different mechanisms involved in the toxicity of mSOD1 have been 
suggested. Catalytic copper is essential for SOD1 activity. It is loaded onto SOD1 
by a copper chaperone for SOD1 (CCS) since free copper is toxic (Furukawa et 
al., 2004). Inefficient incorporation onto SOD1 or impaired shielding of the ion due 
to abnormal SOD1 structure could lead to cellular damage and motor neuron 
degeneration. Mice deficient for CCS showed reduced amount of copper-loaded 
SOD1, but onset and progression of ALS in mSOD1 mice was not modified 
(Subramaniam et al., 2002).  
Cytoplasmic protein accumulations of insoluble proteins were detected in sporadic 
and familial ALS patients as well as mSOD1 mouse models in the affected tissue 
(Watanabe et al., 2001; Furukawa et al., 2006). Those aggregates contain 
ubiquitin (Watanabe et al., 2001), a protein which labels proteins for degradation 
via the proteasome complex. Thus, protein accumulation could impair normal 
protein degradation and affect proteasome machinery.  
Another feature found in ALS are morphological alterations of mitochondria such 
as vacuolated degeneration (Liu et al., 2004) and changes in enzyme activities 
(Jung et al., 2002; Li et al., 2010). It was shown that mSOD1 is recruited to 
mitochondria only in the affected tissue and that this is independent of CCS and 
dismutase activity (Liu et al., 2004). Furthermore, accumulation of mSOD1 with 
mitochondria is accompanied by a damage of mitochondrial bound proteins. The 
mitochondrial genome encodes only for 13 of the 1500 proteins required for 
mitochondrial function. Most of the proteins are nucleus encoded and have to be 
transported from the cytoplasma into the mitochondria (Boillee et al., 2006a). 
Thus, association of mSOD1 with mitochondria could interfere with protein import 
and influence mitochondrial enzyme activity (Liu et al., 2004).  
Another mechanism involved in mSOD1-mediated toxicity might be alterations in 
reactive oxygen (ROS) production. Increased ROS levels were found in the brain 
and spinal cord of mSOD1 mice (Harraz et al., 2008). The enzyme complex 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is a source of 
ROS production. Experiments with mice expressing mSOD1 demonstrated that 
SOD1 regulates NADPH oxidase-dependent superoxide production. SOD1 can 
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regulate the activity of one subunit of the NADPH oxidase. However, this 
regulation is defective in mSOD1 leading to increased superoxide levels (Harraz et 
al., 2008).  
 
1.3.2 Role of microglia in ALS 
Microglial activation was detected in the brain and spinal cord of ALS patients 
(Engelhardt and Appel, 1990; Henkel et al., 2004) and mSOD1 mouse models 
(Hall et al., 1998; Henkel et al., 2006). An inflammatory response including 
microglial activation is initiated before the onset of the disease (Hall et al., 1998). A 
pathological role of microglia in ALS was suggested based on data of animal 
models. Silencing of mSOD1 in neurons extended survival by slowing disease 
onset whereas inactivation of mSOD1 in microglia slowed disease progression 
(Boillee et al., 2006b). Another study using PU.1-deficient mice which lack myeloid 
and lymphoid cells including microglia demonstrated also the involvement of 
microglia in ALS (Beers et al., 2008). On the one hand, PU.1-deficient mice 
received bone marrow transplants from mSOD1 mice resulting in donor-derived 
microglia. No induction of motor neuron injury was induced in these mice. On the 
other hand, PU.1-deficient mice crossed with mSOD1 mice received bone marrow 
transplants from wildtype animals. A slowed motor neuron loss and prolonged 
disease duration and survival were observed in these mice. Both studies indicate 
that neurons are involved in the onset of the disease whereas microglia accelerate 
disease progression.  
Wildtype microglia act less neurotoxic on motor neurons than mSOD1 microglia 
(Beers et al., 2008). Microglia expressing mSOD1 were shown to produce more 
ROS and induce neuronal death. Coculture experiments of rat motor neurons with 
microglia activated with LPS or immunoglobulin G complexes from ALS patients 
demonstrated induced motor neuron injury. Furthermore, this effect could be 
prevented by an iNOS inhibitor demonstrating the involvement of NO in this 
process (Zhao et al., 2004). In addition, mSOD1 affects microglial release of pro-
inflammatory cytokines. Adult microglia expressing mSOD1 were shown to 
produce higher TNFα levels after stimulation with LPS in comparison to wildtype 
cells. However, neonatal microglia showed no difference in TNFα production after 
LPS stimulation (Weydt et al., 2004). A recent publication further demonstrated a 
transformation of mSOD1 microglia from a neuroprotective to a neurotoxic 
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phenotype (Liao et al., 2012). While microglia isolated from ALS mice at disease 
onset were neuroprotective and enhanced motor neuron survival, microglia from 
end-stage of the disease were neurotoxic leading to motor neuron death. These 
findings suggest an increased cytotoxic potential of adult microglia expressing 
mSOD1.  
 
1.4 Aim of the study 
Microglia are the first line of the innate immunity in the CNS involved in tissue 
homeostasis and host defence. However, there are some evidences that microglia 
are involved in neurodegenerative diseases like Alzheimer’s disease, Huntington’s 
disease and amyotrophic lateral sclerosis. Therefore, detailed studies about 
microglial function are crucial. Primary microglia or microglial lines obtained by 
viral transformation are often used for investigation of microglial function. 
However, primary microglia are only available in limited numbers complicating 
most studies while microglial lines might not reflect microglial behavior due to the 
transformation process. 
The first aim of this study was to generate human microglial cell lines (iPSdM) 
derived from induced pluripotent stem cells. Microglial functionality was 
investigated regarding phagocytosis capacity, induction of pro-inflammatory 
cytokines and migratory potential towards chemokines. 
Next, microglial role in SOD1-mediated ALS was investigated. IPSdM were 
transduced with wildtype and three different mutant SOD1 (G37R, G85R and 
G93A). Wildtype and mSOD1 expressing cells were compared regarding 
upregulation of pro-inflammatory cytokines, mitochondrial enzyme activities and 
ROS production. 
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2 Materials and Methods 
2.1  Materials 
2.1.1  Animals and cells 
mouse strains 
Rag2/IL-2R KO mice  
(C57BL/10SgSnAi[KO]γc-[KO]Rag2) 
NIAID, USA (Cao et al., 1995) 
 
cell lines 
HEK293FT Invitrogen GmbH, Germany 
Murine embryonic fibroblasts (MEF) isolated from CD1 mice (E14.5); kindly 
donated by Anke Leinhaas, University 
of Bonn, Germany 
iLB-C-35m-r1 generated and kindly provided by AG 
Brüstle, University of Bonn, Germany 
iPS(foreskin)-1 WiCell Research Institute, USA 
 
2.1.2 Plasmids 
PLP1 Invitrogen GmbH, Germany 
PLP2 Invitrogen GmbH, Germany 
PLP3 Invitrogen GmbH, Germany 
Pll3.7 PGK-eGFP designed and modified by Isabella 
Napoli, AG Neumann 
Pll3.7 PGK-hSOD1 wt-eGFP Plamids donated by AG Clement 
(University of Mainz) and modified by 
Johannes Friese (AG Neumann) 
Pll3.7 PGK-hSOD1 G37R-eGFP 
Pll3.7 PGK-hSOD1 G85R-eGFP 
Pll3.7 PGK-hSOD1 G93A-eGFP 
 
2.1.3 Primer 
GAPDH_for 5’- CTG CAC CAC CAA CTG CTT AG -3’ 
GAPDH_rev 5’- TTC AGC TCA GGG ATG ACC TT -3’ 
TNFα_for 5’- GAC AAG CCT GTA GCC CAT GT -3’ 
TNFα_rev 5’- AGG ACC TGG GAG TAG ATG AGG -3’ 
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iNOS_for 5’- CAG CTG GGC CGT GCA AAC CT -3’ 
iNOS_rev 5’- TGG CAC GGC TGG ATG TCG GA -3’ 
 
2.1.4 Chemicals and Reagents 
1,4-Diazobicyclo-(2.2.2)octan Sigma Aldrich Chemie GmbH, Germany 
Alfazyme PAA Laboratories GmbH, Austria 
Amyloid-β Bachem, Germany 
β-Mercaptoethanol Chemicon Europe, Germany 
B27 supplement (50x)               Gibco, Invitrogen GmbH, Germany 
Bovine serum albumin  Sigma Aldrich Chemie GmbH, Germany 
Collagenase Type IV  Gibco, Invitrogen GmbH, Germany 
ddH2O autoclaved and filtered in the Institute 
D-(+)-Glucose solution (45 %) Sigma Aldrich Chemie GmbH, Germany 
Dimethyl sulfoxide  Sigma Aldrich Chemie GmbH, Germany 
DMEM/F12 (1:1) with L-glutamine and  
  15 mM HEPES 
Gibco, Invitrogen GmbH, Germany 
DMEM with L-glutamine, w/o sodium  
   pyruvate, with 4.5 g/l D-glucose 
Gibco, Invitrogen GmbH, Germany 
EDTA Carl Roth GmbH & Co KG, Germany 
Ethanol Carl Roth GmbH & Co KG, Germany 
Fluoresbrite Polychromatic Red   
  microspheres 1.0 µm 
Polyscience, Inc., Germany 
Fibronectin from bovine plasma Sigma Aldrich Chemie GmbH, Germany 
Fibronectin 0.1 % solution Sigma Aldrich Chemie GmbH, Germany 
Fetal calf serum (FCS) Gibco, Invitrogen GmbH, Germany 
Gelatine from porcine skin Fluka, Sigma Aldrich Chemie GmbH, 
Switzerland 
Glutardaldehyd Sigma Aldrich Chemie GmbH, Germany 
Glycerol Sigma Aldrich Chemie GmbH, Germany 
Knockout serum replacement (KO/SR) Gibco, Invitrogen GmbH, Germany 
Laminin Sigma Aldrich Chemie GmbH, Germany 
L-Glutamine (200 mM) Gibco, Invitrogen GmbH, Germany 
LPS Sigma Aldrich Chemie GmbH, Germany 
LPS Enzo Life Sciences GmbH, Germany 
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Mowiol 4-88 Kremer Pigmente, Germany 
Non-essential amino acids (10 mM) Gibco, Invitrogen GmbH, Germany 
N2 supplement (100x) Gibco, Invitrogen GmbH, Germany 
Normal goat serum Sigma Aldrich Chemie GmbH, Germany 
Paraformaldehyde  Merck KgaA, Germany 
PBS Gibco, Invitrogen GmbH, Germany 
Penicillin/Streptomycin Gibco, Invitrogen GmbH, Germany 
Poly-L-Lysine Sigma Aldrich Chemie GmbH, Germany 
Poly-L-Ornithin Sigma Aldrich Chemie GmbH, Germany 
ROCK Inhibitor Y-27632 Calbiochem, UK 
Saccharose Carl Roth GmbH & Co KG, Germany 
Sialidase (1 U) Roche, Germany 
Sodium pyruvate (100 mM) Gibco, Invitrogen GmbH, Germany 
Tissue Tek, O.C.T.TM compound   Sciences Service GmbH, Germany 
Tris Carl Roth GmbH & Co KG, Germany 
TritonX Sigma Aldrich Chemie GmbH, Germany 
Trypsin (0.25 %) Gibco, Invitrogen GmbH, Germany 
 
2.1.5 Growth Factors and Cytokines 
Recombinant human fibroblast growth   
   factor 2 (rhFGF2) 
R&D Systems GmbH, Germany  
Recombinant human granulocyte- 
   macrophage colony stimulating factor   
   (rhGM-CSF) 
Gibco, Invitrogen GmbH, Germany 
Recombinant human interferon γ  
   (rhIFNγ)  
R&D Systems GmbH, Germany  
Recombinant human tumor necrosis  
   factor α (rhTNFα) 
R&D Systems GmbH, Germany 
Recombinant human  
   CX3CL1/Fractalkine full length 
R&D Systems GmbH, Germany 
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2.1.6 Buffers and Solutions 
0.01 M sodium citrate buffer, pH 6 5.88 g Tri-sodium citrate (dihydrate) 
ad 2 l aqua bidest. 
adjust pH with 1 M HCl 
1 ml Tween 20 
 
Krebs-Hepes-buffer pH=7.4 1.98 g Hepes 
7.60 g NaCl 
0.42 g KCl 
0.29 g CaCl2 
0.049 g MgCl2 
1.98 g glucose 
ad 1 l aqua bidest. 
 
Mowiol 4.8 g Mowiol 4-88 
12 g Glycerol 
24 ml 0.2 mM Tris buffer, pH 8.5 
1.32 g 1,4-Diazobicyclo-(2.2.2)octan 
12 ml aqua bidest. 
 
Gelatine 0.5 g in 500 ml aqua dest. 
 
Poly-L-Ornithin (0.01 mg/ml) 9.2745 g boric acid ad 1 l aqua dest. 
100 mg Poly-L-Ornithin 
 
Saccharose, 30 % 30 % saccharose  
0.1 % sodium azide 
ad 500 ml PBS 
 
2.1.7 Kits 
Lipofectamin 2000 Invitrogen GmbH, Germany 
RNeasy Mini Kit Quiagen, Germany 
SuperScript First-Strand Synthesis  
          System 
Invitrogen GmbH, Germany 
SYBR green  Invitrogen GmbH, Germany 
Colorimetric MTT Kit Millipore Corporation, USA 
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2.1.8 Media 
MEF-medium    DMEM with L-glutamine, without Na-pyruvat,  
   4.5 g/l D-glucose 
0.1 mM NEAA 
1 mM sodium pyruvate 
2 mM L-glutamine 
10 % FCS 
 
iPS-medium DMEM/F12 (1:1) with L-glutamine with HEPES (15 mM) 
20 % knockout serum replacement 
0.1 mM NEAA 
0.1 mM L-glutamine 
0.1 mM β-mercaptoethanol 
25 ng/ml rhFGF2 
 
differentiation medium DMEM/F12 (1:1) with L-glutamine with HEPES (15 mM) 
20 % knockout serum replacement 
0.1 mM NEAA 
0.1 mM L-glutamine 
 
B27-medium DMEM/F12 (1:1) with L-glutamine with HEPES (15 mM) 
2 % B27 
0.2 mM L-glutamine 
15.6 µg/ml D-glucose 
20 ng/ml rhFGF2 
5 µg/ml fibronectin 
 
N2-medium  DMEM/F12 (1:1) with L-glutamine with HEPES (15 mM) 
1 % N2 supplement 
0.5 mM L-glutamine 
15.3 µg/ml D-glucose 
100 µg/ml penicillin/streptomycin 
 
freezing medium 50 % FBS 
40 % medium 
10 % DMSO 
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2.1.9 Antibodies 
 
Primary antibodies 
 
Antigen Reactivity Host Company 
    
CD11b mouse, human rat BD Pharmingen, Germany 
CD11c-Bio mouse, human hamster BD Pharmingen, Germany 
CD14 human mouse Exbio, Czech Republic 
CD16/32 (Fc block) mouse, human rat BD Pharmingen, Germany 
CD16/32-Bio mouse, human rat BD Pharmingen, Germany 
CD29 mouse, human rat BD Pharmingen, Germany 
CD34 human mouse Exbio, Czech Republic 
CD36 mouse, human mouse BD Pharmingen, Germany 
CD40 human mouse Exbio, Czech Republic 
CD45 mouse, human rat BD Pharmingen, Germany 
CD49d mouse, human rat BD Pharmingen, Germany 
CD68 mouse, human rat Serotec, USA 
CD86 mouse, human rat BD Pharmingen, Germany 
CD206 human mouse Acris, Germany 
CX3CR1 mouse, human rabbit ProSci Incorporated 
I-A/I-E-Bio  
   (MHC class II) 
mouse, human rat BD Pharmingen, Germany 
GFAP mouse rabbit Dako, Germany 
GFP  mouse Chemicon, Germany 
Iba1 mouse, human rabbit Wako, Germany 
Nestin human mouse Millipore, USA 
Siglec-11-Bio human goat R&D Systems GmbH,    
   Germany 
SOD1 human, rat rabbit Wako, Germany 
TUJ1 human rabbit Covance, USA 
isotype IgG1 κ  mouse BD Pharmingen, Germany 
isotype IgA  mouse BD Pharmingen, Germany 
isotype IgG2aκ  rat BD Pharmingen, Germany 
isotype IgG2bκ  rat BD Pharmingen, Germany 
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isotype IgG1-Bio  armenian 
hamster 
eBioscience, USA 
isotype IgG2aκ-Bio  rat BD Pharmingen, Germany 
isotype IgG2bκ-Bio  rat BD Pharmingen, Germany 
 
Additional staining reagents 
 
4',6-diamidino-2-phenylindole (DAPI) Sigma Aldrich Chemie GmbH, Germany 
dihydroethidium (DHE) Invitrogen GmbH, Germany 
 
Secondary antibodies 
 
Fluorophore Reactivity Host Company 
    
Phycoerythrin  mouse goat Jackson Immunoresearch, UK 
Phycoerythrin rat goat Jackson Immunoresearch, UK 
Phycoerythrin rabbit goat Jackson Immunoresearch, UK 
Phycoerythrin-  
   Streptavidin 
Biotin goat Jackson Immunoresearch, UK 
Alexa488 mouse goat Invitrogen GmbH, Germany 
Alexa488 rabbit goat Invitrogen GmbH, Germany 
Cy3 rabbit goat Dianova, Germany 
Cy3 rat goat Dianova, Germany 
Cy3-Streptavidin Biotin goat Dianova, Germany 
 
2.1.10 Consumable supplies 
6-well Tissue Culture Plate Cellstar, Greiner Bio One, Germany 
8.0 µm Culture Plate Inserts 12 mm  
   Diameter 
Millipore, Germany 
Bacterial dishes (100 mm) Becton Dickinson GmbH, Germany 
Corning Cell Scraper Sigma Aldrich Chemie GmbH, Germany 
Cell strainer Becton Dickinson GmbH, Germany 
Cryovials (2 ml) Nunc GmbH & Co KG, Germany 
Tissue Tek, Disposable Vinyl 
Specimen Molds 
Sciences Services GmbH, Germany 
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Falcon tubes (15 ml) Cellstar, Greiner Bio One, Germany 
Falcon tubes (50 ml) Sarstedt Ag & CoKG, Germany 
Filtropur (0.25 µm, 0.4 µm) Sarstedt Ag & CoKG, Germany 
Graduate pipette Tipps (10 µl,  
   100 µl, 1000 µl) 
Starlab GmbH, Germany 
Lab-Tek Chamber Slide w/ Cover  
   Permanox Slide Sterile 4 Well 
Labomedic, Germany 
Latex gloves Ansell Healthcare Europe NV, Belgium 
Microscope cover glasses P. Marienfeld GmbH, Germany 
Needles Sterican, Braun Meisungen AG, Germany 
Nitrile gloves Ansell Healthcare Europe NV, Belgium 
Pasteur pipettes Brand GmbH & Co KG, Germany 
Pipettes (5 ml, 10 ml, 25 ml) Sarstedt AG & Co KG, Germany 
Safe-seal micro tubes (0.5 ml,  
  1.5 ml, 2 ml) 
Sarstedt Ag & Co KG, Germany 
Syringes (5 ml, 10 ml) Omnifix, Braun Meisungen AG, Germany 
Tissue Culture Dishes (35 mm,  
  60 mm, 100 mm) 
Sarstedt Inc., USA 
Vacuum driven disposable bottle top  
   filter 
Millipore Corporation, USA 
 
2.1.11 Technical equipment  
- 20°C freezer Liebherr, Bulle, Switzerland 
+ 4°C fridge Liebherr, Bulle, Switzerland 
BD FacsCalibur BD Bioscience, Germany 
Cell MateII (pipette boy) Thermo Fisher Scientific Inc., USA 
Confocal Microscope Olympus, Germany 
Envision 2104 Multilabel Reader Perkin Elmer, USA 
Eppendorf Mastercycler epgradient S Eppendorf, Germany 
Hera cell 150 (incubator) Heraeus Holding GmbH, Germany 
Hera freeze (-80°C freezer) Heraeus Holding GmbH, G ermany 
Hera safe (laminar-air flow workbench) Kendro Laboratory Products GmbH,    
   Germany 
Mefaguge1.0R (centrifuge) Heraeus Holding GmbH, Germany 
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Microscopes Carl Zeiss AG, Germany 
 HBO 50/AC 
 Axiovert200M 
 ImagerZ1 
 Fluoview FV1000 Olympus 
Microtom HM 560 M Microm International, Germany 
Pipettes (10 µl, 100 µl, 1000 µl) Eppendorf AG, Germany 
Systec D-150 (autoclave) Systec GmbH, Germany 
Thermomixer compact Eppendorf AG, Germany 
Water bath WB/OB7-45 Memmert GmbH & CoKG, Germany 
 
2.1.12 Software 
Cell Quest Pro BD Bioscience, USA 
FlowJo TreeStar, USA 
ImageJ 1.43m National Institute of Health, USA 
Olympus Fluoview FV1000 Olympus, Germany 
SPSS IBM, Germany 
Wallac Envision Manager 1.12 Dazdaq, UK 
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2.2  Methods 
2.2.1 Generation of induced pluripotent stem cell derived 
microglial precursors (iPSdM)  
For maintenance and expansion of human induced pluripotent stem (iPS) cells, 
cells were cultured in chemically defined medium in the presence of 10 ng/ml 
rhFGF2 on a mouse embryonic fibroblast layer. Cells were detached using 
collagenase IV, collected in a tube and centrifuged at 800 rpm for 3 min. Cell pellet 
was resuspended in differentiation medium and cultivated on non-adherent 
bacterial dishes to induce embryoid body (EB) formation. EBs were kept in 
suspension for 8 days for spontaneous differentiation. EBs were plated on poly-L-
ornithin / fibronectin - coated dishes and allowed to attach for 2 days. Neural 
precursors were selected for 14 days in B27-medium supplemented with 20 ng/ml 
rhFGF2 and 5 µg/ml fibronectin. Medium was changed to N2-medium 
supplemented with 20 ng/ml rhFGF2 and 10 ng/ml laminin. Differentiation of 
microglial precursors was initiated by withdrawal of the growth factors after 10 
days of expansion. After 160 days of differentiation, first microglial precursors 
appeared in the culture identified by morphology. To enhance cell proliferation 
100 ng/ml rhGM-CSF were added to the media after the development of the first 
microglial precursors. Microglial precursors were mechanically isolated with a 
micropipette under microscope and cultivated at high density on poly-L-lysin -
 coated dishes in N2-medium supplemented with 100 ng/ml rhGM-CSF. After 
several days in culture, microglial precursor cells started to proliferate. Microglial 
precursors proliferated without the addition of growth factors after some passages 
and could be cultivated in N2-medium on non-coated cell culture dishes. Cells 
could be passaged 1:3 till 1:5 twice a week. In total, 4 iPS-derived microglial 
precursor (iPSdM) lines out of two different iPS cell lines were generated. IPSdM 
line 1 and 4 are derived from iLB-C-35m-r1 and line 2 and 3 from iPS(foreskin)-1. 
 
2.2.2 Maintenance of iPSdM  
IPSdM were cultivated in N2-medium at 5 % CO2 at 37°C. Upon 80-90 % 
confluency, cells were split 1:3 till 1:5 twice a week using 0.25 % trypsin. IPSdM 
could be frozen slowly in N2-medium supplemented with 10 % DMSO and 50 % 
FCS. 
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2.2.3 Proliferation assay 
For proliferation assay, 200 000 cells were seeded in 6 cm dishes in N2-medium. 
Total cell number was counted after 24 h, 48 h, 72 h and 96 h using a Neubauer 
chamber. 
 
2.2.4 Analysis of cell viability 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-dipenyl tetrasodium bromide) assay was 
used to check for cell viability. 50 mg of the MTT reagent were diluted in 10 ml 
PBS, pH 7.4. For detection 15 000 cells were seeded in a 96-well flat bottomed 
tissue culture plate in N2-medium with a final volume of 100 µl. Cells were 
incubated at 37°C, 5 % CO 2. On the next day, 10 µl MTT dilution were added into 
each well and mixed by tipping to the plate. After 4 h incubation at 37°C, 5 % CO 2, 
100 µl of 0.04 M HCl in isopropanol were added into each well and mixed 
thoroughly. The absorbance at 570 nm and 630 nm (as reference) was measured 
using an ELISA reader.  
 
2.2.5 Immunocytochemistry of cultured cells  
For immunocytochemistry, human cultures and iPSdM were washed 3 x with PBS 
and then fixed with 4 % paraformaldehyde (PFA) for 10 min. Cultures were 
blocked with 10 % BSA, 5 % normal goat serum and for intracellular markers 
additionally with 0.1 % Triton X for 30 min at room temperature (RT). Human cells 
were stained with antibodies directed against Iba1 (1 µg/ml), CD45 (1 µg/ml), 
CD68 (2 µg/ml), SOD1 (1:250), nestin (2 µg/ml) and βIII-tubulin (clone TUJ1, 
1 µg/ml). All primary antibodies were incubated over night at 4°C. Afterwards, 
cultures were washed 3 x for 5 min with PBS. Primary antibodies were detected 
with Cy3-conjugated goat-anti-rat (2.5 µg/ml), goat-anti-rabbit (2.5 µg/ml), 
Alexa488-conjugated goat-anti-rabbit (4 µg/ml) and goat-anti mouse (4 µg/ml). 
Secondary antibodies were incubated for 90 min at RT in the dark. Cultures were 
again washed 3 x for 5 min with PBS and counterstained with DAPI (0.1 µg/ml) for 
30 s. After 3 x washing with PBS, cells were covered with Mowiol and cover slides. 
Stained cultures were stored at 4°C. 
 
 
Materials and Methods 21 
2.2.6 Flow cytometry  
Cells were unstimulated or stimulated for 4 days with 1 µg/ml LPS or 
1000 U/m IFNγ. After a 3 x washing period with PBS, cells were collected from the 
cell culture dish using a cell scraper. For Siglec-11 detection, cells were pre-
incubated with sialidase (1:400) for 2.5 h in medium at 37°C and 5 % CO 2. 
CD16/32 was used as Fc block (4 µg/ml) for cells stained with biotinylated 
antibodies adding 5 min before the first antibody. Cells were stained for 1 h at 4°C 
using the following primary antibodies: CD11b (2.5 µg/ml), CD11c-Bio (2.5 µg/ml), 
CD14 (5 µg/ml), CD16/32-Bio (2.5 µg/ml), CD29 (2.5 µg/ml), CD34 (5 µg/ml), 
CD36 (2.5 µg/ml), CD40 (5 µg/ml), CD45 (2.5 µg/ml), CD49d (2.5 µg/ml), CD86 
(2.5 µg/ml), CD206 (5 µg/ml), I-A/I-E-Bio (2.5 µg/ml) and CX3CR1 (2.5 µg/ml). The 
corresponding isotype control was used as control. After 3 x washing, cells were 
incubated with the secondary antibody for 30 min at 4°C in the dark. Primary 
antibodies were detected with PE-conjugated goat-anti-mouse, goat-anti-rat, goat-
anti-rabbit or PE-Streptavidin (2.5 µg/ml). Cells were washed again with PBS, 
diluted in 500 µl PBS and marker expression was analyzed using flow cytometry.  
 
2.2.7 Western Blot Analysis 
Western Blot analysis was done by AG Clement, University of Mainz. Cells were 
harvested in TBS extraction buffer containing 2 % SDS and 10 % sucrose and 4 x 
sonificated. BCA-based protein determination was performed according to 
manufacturer’s protocol (Thermo Fisher). 12 µg of protein were separated on 12 % 
SDS-PAGE gels and transferred on nitrocellulose. Endogenous SOD1 and SOD1-
GFP fusion proteins were detected by a rabbit monoclonal antibody from 
Epitomics and a corresponding HRP-coupled secondary antibody (Dianova). 
Enhanced luminescent signals were detected with the LAS3000 system (Fuji) and 
quantified by the ImageJ software. 
 
2.2.8 Gene transcript analysis 
For gene transcript analysis, 200 000 cells of iPSdM were seeded in 6 cm dishes 
and stimulated with either 1000 ng/ml LPS, 1000 U/ml rhIFNγ or 100 ng/ml 
rhTNFα. Unstimulated cells served as control. After 6 h of stimulation RNA was 
extracted using RNeasy Mini Kit. Right after the isolation reverse transcription was 
performed following the Invitrogen protocol for SuperScript First-Strand Synthesis 
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System. Transcribed cDNA was dilutet to 250 ng/µl. For real-time RT-PCR 
following mix was prepared in 96-well-plate: 12.5 µl SYBR Green Mix, 4 µl cDNA, 
1 µl of each primer (10 pmol/µl) and 6.5 µl aqua dest. The same mix with aqua 
dest. instead of cDNA was used as non-template-control. Then, the plate was 
covered with a plastic lid and the following program was run: 
Cover T° = 105°C 
 
Initial denature: 95°C  10 min 
Denature:   95°C  15 s 
Annealing:   60°C  20 s 
Elongation:   72°C  30 s 
Amplification:  for 40 cycles 
To asses if a specific product was obtained a dissociation curve analysis was 
performed using the following program: 
95°C  15 s 
60°C  15 s 
95°C  15 s 
ramp rate 20 min 
 
2.2.9 Microsphere beads phagocytosis assay  
To analyze microglial cells for phagocytosis capacity of beads, 100 000 cells per 
condition were seeded per well in 6-well-plates in 2 ml N2-medium and cultured at 
37°C, 5 % CO 2. The next day, cells were stimulated with 500 ng/ml LPS or 
1000 U/ml rhIFNγ for 24 h. Unstimulated cells were used as control. Cells were 
incubated with 5 µl microspheres beads for 30 min at 37°C, 5 % CO 2 and then 
detached using trypsin. After centrifugation at 1200 rpm for 3 min cells were 
resuspended in 500 µl PBS and analyzed using flow cytometry. Cells that had 
phagocytose more than 1 bead were taken into account. 
 
2.2.10 Aβ phagocytosis assay  
To analyze microglial cells for phagocytosis capacity of amyloid β, 40 000 cells per 
condition were seeded per well in chamber slides. Cells were kept unstimulated or 
stimulated with 500 ng/ml LPS or 1000 U/ml rhIFNγ for 24 h at 37°C, 5 % CO 2 and 
then incubated with biotinylated amyloid β (10 µg/ml) for 1.5 h at 37°C, 5 % CO 2. 
Materials and Methods 23 
Cells were stained for Iba1 and amyloid β as described above and percentage of 
phagocytosing cells was analyzed by fluorescence microscopy. 
 
2.2.11 Migration assay  
Cells were detached using trypsin and 100 000 cells per condition were seeded in 
the upper chamber of a transwell-system in medium to settle down. After 1 h cells 
were treated with different concentrations of rhCX3CL1 (0, 5, 10, 15 and 20 ng/ml) 
in the lower chamber for 4 h at 37°C, 5 % CO 2. As control for undirected migration 
20 ng/ml rhCX3CL1 were added into both chambers. Using a cotton bud cells of 
the upper chamber were removed. Cells that had migrated to the lower chamber 
and to the backside of the membrane were counted. The count occurred under 
bright field and all 4 big squares of the Neubauer chamber were analyzed. 
 
2.2.12 Detection of ROS by dihydroethidium 
Cells were seeded with a density of 30 000 cells per well in chamber slides. Cells 
were stimulated for 24 h with 1000 ng/ml LPS, 1000 U/ml rhIFNγ or with 500 ng/ml 
rhTNFα for 20 min. To detect ROS production cells were washed 3 x with Krebs-
HEPES-buffer and stained for 15 min at 37°C with 30  µM dihydroehidium (DHE). 
Cells were washed again three times with Krebs-HEPES-buffer and fixated with 
0.25 % glutaraldehyde in 4 % PFA. Cells were counterstained with DAPI 
(0.1 µg/ml) and mounted with Mowiol 4-88 and cover slides. Quantification was 
done using confocal microscopy and ImageJ. Per experiment and condition, 3 to 5 
pictures were analyzed. 
 
2.2.13 Mitochondrial analysis 
Analysis was done by AG Kunz, University of Bonn. For analysis of complex I 
(NADH:CoQ 1 Oxidoreductase) the activity of rotenone-sensitive NADH:CoQ 1 
oxidoreductase was measured at 30°C using a dual-wa velength 
spectrophotometer (Aminco DW 2000, SLM Instruments,  Rochester,  NY)  at  
340-380  nm  (ε red-ox = 5.5 mM- 1 cm- 1) as described previously (Wiedemann et al., 
2000). The reaction medium contained of 50 mM KCl, 1 mM EDTA, 10 mM TRIS-
HCl (pH 7.4), 1 mM KCN, 100 µM CoQ 1 and 150 µM NADH. The assay was 
initiated by addition of the sample and the velocity of NADH oxidation was 
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monitored. To determine the rotenone-insensitive NADH oxidation rate, 20 µM 
rotenone were added to the assay mixture after 2 min. Activities were determined 
as the differences between the total NADH oxidation rate and the rotenone-
insensitive NADH oxidation rate. For analysis of complex IV (Cytochrome c 
Oxidase) the cytochrome c oxidase activities were measured at 30°C in 0.1 M 
potassium phosphate buffer (pH 7.4) containing 0.02 % laurylmaltoside (Sigma, 
Deisenhofen, Germany) monitoring the oxidation of ferrocytochrome c in its band 
at the wavelength pair 510-535 nm using a dual wavelength spectrophotometer 
(Aminco  DW  2000,  SLM  Instruments) as described previously (Wiedemann et 
al., 2000). For citrate synthase analysis the activity of citrate synthase was 
determined at 30°C by a standard method (Bergmeyer) . The protein content of the 
cell homogenates was determined using a protein assay kit based on Peterson's 
modification of the micro-Lowry method according to the instructions of the 
manufacturer (Sigma).   
 
2.2.14 Virus production and transduction of iPSdM 
For lentiviral production the plasmid with gene of interest was transfected together 
with three packaging plasmids (PLP1, PLP2, PLP3) into HEK293FT cells (done by 
Johannes Friese). For transfection, Lipofectamin 2000 was used following manual 
instructions. Medium was changed 16 h post-transfection. Supernatant was 
collected 48 h and 72 h after transfection. For transduction, iPSdM1 were seeded 
in 10 cm dishes in culture medium and viral particles were added to media for 3 
days. In total, iPSdM1 were transduced 4 times with GFP, hSOD1 wt-GFP, 
hSOD1 G37R-GFP, hSOD1 G85R-GFP and hSOD1 G93A-GFP. Afterwards cells 
were sorted via FACS sorting using the GFP-tag. 
 
2.2.15 Transplantation of GFP-iPSdM into immunodeficient mice  
GFP expressing iPSdM were used for transplantation into 6 weeks old Rag2/IL-2R 
KO mice. Cells were detached using trypsin, centrifuged at 1200 rpm for 3 min and 
pellet was diluted in 1 % DNase containing cyto-buffer with a concentration of 
150 000 cells/µl. Mice were anesthetized with Fentanyl, Midazolam and 
Medetomidin and Isofluran/O2. Mice were fixed, sculls were shaved and 1 µl of the 
cell suspension was applied over 2 min in a 0.52 mm prepared borehole. Cells 
were transplanted into the left side of the hippocampus (coordinates referred to 
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Bregma: posterior 2.4/ lateral 1.5/ ventral 1.4-1.6). Afterwards, the borehole was 
fixed with bone wax, washed with antiseptic solution and the wound was closed 
with a stapler. To avoid inflammatory response mice received Carprofen (5 ng per 
g body weight). After 3 and 9 weeks mice were transcardially perfused with PBS 
following 4 % PFA. The brain was isolated and post fixated for 1 day in 4 % PFA 
and then cryoprotected in 30 % sucrose in PBS. Organs were embedded in 
TissueTek, stored at -80°C for 20 min and 20 µm cry osections were collected on 
glass slides. For detection, sections were stained as described above and 
analyzed using confocal microscopy. 
 
2.2.16 Immunohistochemistry of brain slices  
Brain slices were once washed with PBS for 5 min. Slices were blocked with 10 % 
BSA, 0.5 % normal goat serum and 0.1 % Triton X in PBS for 90 min at RT in a 
wet chamber. Cells were incubated with primary antibodies directed against CD68 
(2 µg/ml), GFAP (1 µg/ml) and GFP (1:500) over night at RT. The next day, cells 
were washed 3 x with PBS for 5 min and incubated with the secondary antibodies 
Cy3-conjugated goat-anti-rabbit or goat-anti-rat (3 µg/ml) and Alexa488-
conjugated goat-anti-mouse (2 µg/ml) for 2 h at RT in the dark. Slices were 
washed 3 x for 5 min with PBS and then counterstained with DAPI (0.5 g/l) for 
10 min at RT. Slices were washed again with PBS and covered with Mowiol and 
cover slides and stored at 4°C. 
 
2.2.17 Statistical analysis  
Data are presented as mean ± SEM of at least 3 independent experiments. Data 
were analyzed by student t-test for two groups only or ANOVA for more than two 
groups using SPSS computer software. 
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3 Results 
3.1 Generation and characterization of human microglial  
      precursor lines 
Microglia represent a crucial target for neuroimmunological research due to their 
manifold involvement in the pathology of neurodegenerative diseases. However, 
human primary microglia are only available in very limited numbers, thus classical 
studies are difficult to perform. Two human microglial cell lines were developed to 
overcome this problem (Janabi et al., 1995; Nagai et al., 2001; Nagai et al., 2005). 
However, these cells might exhibit an altered cytokine profile and changes in their 
behavior due to the transformation process. Therefore, the aim of this work was to 
generate a protocol for the differentiation of human induced pluripotent stem (iPS) 
cells to microglial precursors. 
 
3.1.1 Generation of microglial cells derived from human induced  
          pluripotent stem cells (iPSdM) 
Microglia develop during primitive haematopoiesis in the fetal yolk sac from 
immature macrophages (Ginhoux et al., 2010; Prinz et al., 2011; Saijo and Glass, 
2011). A differentiation protocol allowing co-development of yolk sac-like 
macrophages and neural progenitors was developed to recapitulate this 
developmental program under culture conditions (Fig. 3.1). 
Human iPS cells derived from adult skin or foreskin fibroblasts were used for the 
differentiation protocol. IPS cells were cultivated in a defined medium 
supplemented with FGF2 on an irradiated embryonic mouse fibroblast layer (Fig. 
3.2 A). The morphology of iPS cells can differ depending on the species they are 
obtained from. Human iPS cells build circular, flat colonies with a well-defined 
shape. Losing their defined shape and building gaps in their colony structure is a 
sign for beginning of differentiation in these cells. To induce spontaneous 
differentiation, iPS cells were detached and cultivated on non-adherent dishes in 
the absence of a fibroblast layer and self-renewal factors. Embryoid bodies (EBs) 
differentiated spontaneously (Fig. 3.2 A), displaying a solid round structure. Seven 
days old EBs were stained positive for the neuronal precursor marker nestin and 
for the macrophage or microglial markers Iba1 and CD45, respectively (Fig. 3.1 
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and 3.2 B). Nestin positive cells were located next to CD45 and Iba1 positive cells 
indicating that at this stage neuronal cells as well as immature macrophages 
developed. EBs were plated on poly-L-ornithin and fibronectin-coated culture 
dishes in B27-medium supplemented with FGF2 and fibronectin to induce neural 
differentiation (Fig. 3.1 and 3.2 A). Cells started to grow out and were expanded in 
N2-medium supplemented with FGF2 and laminin. Differentiation of microglia was 
induced after withdrawal of FGF2. Microglial-like cells appeared as shiny round 
cells and developed within some weeks in a mixed culture of glial and neuronal 
cells (Fig. 3.1). CD45 positive microglial-like cells were found next to βIII-tubulin 
positive neuronal cells (Fig. 3.1 and 3.2 C). Microglial-like cells started to 
proliferate after some days. GM-CSF was added to the culture to enhance cell 
survival and proliferation (Fig. 3.1). Microglial-like cells could be isolated and 
expanded on cell culture dishes.  
 
  
 
Fig. 3.1: Schematic drawing of the differentiation of human iPS cells to microglial 
precursors. Human iPS cells spontaneously differentiated within 8 days into embryoid bodies 
(EBs) on non-adherent dishes in the absence of FGF2. EBs were plated on extracellular matrix- 
coated dishes in B27-medium supplemented with FGF2 for 14 days. Neural and myeloid 
progenitors started to develop and were expanded for 10 days in N2-medium supplemented with 
FGF2. After withdrawal of FGF2, microglial precursors co-developed with neurons in N2-medium. 
Microglial precursors were mechanically isolated on day 160 and were expanded for 10 days in N2-
medium supplemented with GM-CSF to obtain a microglial line on day 170 that stably proliferated 
in N2-medium without any growth factors. 
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Fig. 3.2: Differentiation of iPS cells into microglial precursor. A. Phase contrast images from 
the differentiation procedure. Human iPS cells were cultured on an irradiated mouse embryonic 
fibroblast layer. IPS cells were detached and spontaneously differentiated into embryoid bodies 
(EBs). EBs were plated and differentiated into neural and myeloid progenitors. Scale bars: 100 µm. 
B. Immunofluorescence images of EBs. EBs were stained positive for nestin, Iba1 and CD45. 
Scale bars: 100 µm. C. Immunostaining of differentiation culture (maturation of myeloid cells) 
stained with an antibody directed against the myeloid marker CD45. CD45-positive cells were 
detected within DAPI stained cells. Phase contrast image shows these cells within a mixed culture. 
Scale bar: 50 µm. 
 
Results 29 
3.1.2 Selection and generation of microglial lines 
Cells with a microglial-like morphology developed about 4 month after withdrawal 
of FGF2 and started to proliferate after some days. These cells were round, with a 
bright shining cell body and could be distinguished from neurons by their 
comparatively bigger cell body and the absence of processes. Microglial-like cells 
were mechanically isolated and cultured at 80-90 % density in medium 
supplemented with GM-CSF to enhance cell survival. After some days cells 
started to proliferate and could be cultivated on cell culture dishes in N2-medium 
without additional growth factors. Twice a week iPS-derived microglial precursors 
(iPSdM) were passaged between 1:3 to 1:5. In total, four different microglial lines 
out of 2 different iPS cell lines could be generated. The iPS cell line iLB-C-35m-r1 
was differentiated into iPSdM line 1 and 4 and the iPS(foreskin)-1 line was 
differentiated into iPSdM line 2 and 3. 
Microglial identity could be confirmed via immunocytochemistry using antibodies 
directed against the microglial marker proteins Iba1 and CD68. A co-localized 
staining of Iba1 and CD68 could be detected throughout the cytoplasm (Fig. 
3.3 A).  
All four microglial lines showed a similar morphology. The phenotype of the 
microglial precursors varied from a ramified structure with several processes to a 
completely rounded cell morphology (Fig. 3.3 B). Microglial cells showed long-term 
proliferation and did not change their morphology until at least passage 25. 
Proliferation assay was performed to characterize the growth rate of the iPSdM 
lines. A defined cell number of iPSdM was seeded and the cells were counted 
every 24 hours for a total of 4 days (Fig. 3.3 C). All four microglial lines showed 
similar growth behaviors with a mean doubling time of 24.6 ± 1.1 h (iPSdM1), 
26.3 ± 2.0 h (iPSdM2), 27.1 ± 1.4 h (iPSdM3) and 25.4 ± 1.4 h (iPSdM4). 
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Fig. 3.3: Establishment of microglial precursor lines from iPS cells. A. Immunostaining of 
induced pluripotent stem cell derived microglial precursor (iPSdM) lines 1, 2, 3 and 4. Cells were 
stained positive for the microglial marker proteins Iba1 and CD68. Scale bars: 100 µm. 
B. Representative phase contrast image of iPSdM line 1. IPSdM were round or had an elongated 
shape with 2 or more processes (see arrows). Scale bar: 100 µm. C. Growth rate of four iPSdM 
lines. All iPSdM lines showed a similar growth behavior with a mean doubling time of 24.6 ± 1.1 h 
(iPSdM1), 26.3 ± 2.0 h (iPSdM2), 27.1 ± 1.4 h (iPSdM3) and 25.4 ± 1.4 h (iPSdM4). Data are 
presented as mean ± SEM of three independent experiments. 
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3.1.3 Protein expression profile of iPSdM 
Flow cytometry analysis was performed to check for surface marker expression 
and to further confirm microglial identity. The expression profile is exemplarily 
shown in Fig. 3.4 for iPSdM1.  
All iPSdM lines showed a similar expression of the analyzed markers. A strong 
expression of CD11b, CD11c, CD16/32, CD36, CD40, CD45, CD49d (integrin α4), 
CD86 (B7.2), CD206 (mannose receptor) and CX3CR1 (fractalkine receptor) could 
be detected by all iPSdM lines. While iPSdM line 1 to 3 showed a strong 
expression of CD11b, this surface marker was expressed lower by iPSdM4. CD29 
(integrin β1), MHC class II protein and sialic acid binding Ig-like lectins-11 (Siglec-
11) were weakly expressed by all four microglial lines. In contrast, the stem cell 
marker CD34 was not expressed in any iPSdM line indicating that the microglial 
lines showed no stem cell properties anymore. CD14, an associated co-receptor of 
the LPS receptor complex, was not expressed in unstimulated cells by iPSdM line 
1 and 4 whereas it was slightly expressed by line 2 and 3. However, stimulation 
with LPS or IFNγ for 4 days increased the expression of CD14 (Fig. 3.4 B). Flow 
cytometry data indicate that the iPSdM lines express surface markers typical for 
microglia and that the expression of these markers remains stable up to passage 
25 (data not shown). 
 
Due to highly comparable results between the four iPSdM lines, in further 
experiments iPSdM1 has been used as a model line for the investigation of the 
functional characteristics. 
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Fig. 3.4: Representative pictures of iPSdM1 surface marker expression. Representative 
pictures of flow cytometry analysis of iPSdM1. A. IPSdM1 showed expression of the microglial 
markers CD11b, CD11c, CD16/32, CD36, CD40, CD45, CD49d, CD86, CD206 and CX3CR1. 
Expression of CD29, MHC class II and Siglec-11 was very low on iPSdM1. The stem cell marker 
CD34 was not expressed. Signal from isotype control antibodies are shown in red, from surface 
markers are shown in blue. B. CD14 expression was not detected in unstimulated iPSdM1 while it 
was upregulated after stimulation for 96 h with LPS (1000 ng/ml) or IFNγ (1000 U/ml). 
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3.1.4 Relative cytokine gene transcription of iPSdM 
One typical feature of microglia is the inducibility of pro-inflammatory cytokines 
after stimulation. Therefore, the transcript levels of TNFα and iNOS in iPSdM were 
analyzed using real-time RT-PCR (Fig. 3.5). Microglial precursors were stimulated 
with either LPS or IFNγ for 6 h. Unstimulated cells were used as control and set as 
1. LPS and IFNγ stimulation had no impact on iNOS gene transcription 
(1.5 ± 0.4 fold and 1.2 ± 0.4 fold). In contrast, LPS stimulation significantly 
increased mRNA transcription of TNFα in iPSdM to 3.3 ± 0.5 fold (p = 0.009). 
However, IFNγ stimulation only led to a slight increase in gene transcription to 
1.6 ± 0.4 fold. Data indicate that production of the pro-inflammatory cytokine TNFα 
could be significantly induced by LPS stimulation in iPSdM. 
 
 
 
Fig. 3.5: Real-time RT-PCR analysis of iNOS and TNFα gene transcription by iPSdM1. 
IPSdM1 were unstimulated (control) or stimulated for 6 h with LPS (1000 ng/ml) or IFNγ 
(1000 U/ml). Both stimulations had no impact on iNOS gene transcription. Stimulation of iPSdM 
with LPS resulted in an increase of TNFα transcript levels, whereas IFNγ treatment did not alter the 
TNFα level. Values were normalized to GAPDH and control were set as 1. Data are presented as 
mean ± SEM of 6 independent experiments. ANOVA post-hoc Bonferroni p-values vs. control: 
** p ≤ 0.01.  
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3.1.5 Phagocytosis capacity of iPSdM 
The phagocytosis capacity of microglia is an important functional hallmark. It has 
been shown that microglia are able to phagocytose amyloid β (Aβ) in vitro. The 
aggregation of Aβ is a pathological characteristic of Alzheimer’s disease. 
Therefore, iPSdM were investigated regarding their phagocytosis capacity of Aβ 
and microsphere beads.  
The phagocytosis assay with Aβ required the incubation of iPSdM with biotinylated 
Aβ. Microglial precursors were labelled with an antibody directed against Iba1. 
Using confocal microscopy and 3D reconstruction Aβ could be detected within the 
Iba1 positive microglial cells (Fig. 3.6 A). Quantification of Aβ positive cells 
revealed that 18.1 ± 3.3 % of the cells phagocytosed Aβ. To investigate the effect 
of a pro-inflammatory stimulation on phagocytosis behavior of microglial 
precursors, iPSdM were stimulated for 24 h with either LPS or IFNγ. Cells which 
have phagocytosed Aβ were counted and standardized to the total cell number 
(Fig. 3.6 B). LPS or IFNγ stimulated iPSdM were compared to unstimulated cells 
which were used as control and set as 100 %. Aβ phagocytosis was significantly 
increased to 196.6 ± 22.6 % (p = 0.006) after LPS stimulation and to 
200.1 ± 21.2 % (p = 0.005) after IFNγ stimulation in comparison to the control 
(100.0 ± 17.3 %). Nearly no difference in phagocytosis capacity of Aβ could be 
observed between both stimulations. In summary, it could be determined that 
iPSdM took up Aβ and showed a significant increase in Aβ phagocytosis after 
stimulation with either LPS or IFNγ in comparison to the unstimulated control. 
Additionally, the phagocytosis rate of iPSdM regarding microsphere beads was 
investigated. Microglial precursors were incubated with fluorescent labeled 
microsphere beads and analyzed using flow cytometry (Fig. 3.6 C). Cells without 
beads incubation served as negative control. The number of iPSdM phagocytosing 
more than 1 bead was calculated. In the unstimulated sample (control), 
32.5 ± 5.7 % of the total cells showed beads uptake. Next, iPSdM were stimulated 
with either LPS or IFNγ for 24 h (Fig. 3.6 C+D) to detect whether pro-inflammatory 
stimulation would lead to an increased beads phagocytosis. Unstimulated cells 
were used as control and set as 100 %. LPS stimulation resulted in an increased 
uptake of microsphere beads to 128.5 ± 24.2 %. No effect of IFNγ stimulation on 
beads uptake could be observed (98.0 ± 16.8 %) in comparison to the 
unstimulated control (100.0 ± 17.3 %). In summary, iPSdM were able to 
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phagocytose microsphere beads, but uptake of beads could not be significantly 
increased with LPS or IFNγ treatment. 
 
 
 
Fig. 3.6: Phagocytosis capacity of iPSdM1. A. Representative picture of Iba1 stained iPSdM1 
phagocytosing amyloid β (Aβ). Biotinylated Aβ stained with Cy3 was detected inside the Iba1 
positive microglial cells by confocal imaging and 3D reconstruction. B. Quantification of Aβ uptake 
by microglia. IPSdM1 were either untreated (control) or stimulated with 500 ng/ml LPS or 
1000 U/ml IFNγ for 24 h. IPSdM1 showed an increased phagocytosis of fibrillary Aβ after 
stimulation with LPS or IFNγ. Data are presented as mean ± SEM of 4 independent experiments. 
ANOVA post-hoc Bonferroni p-values vs. control: ** p ≤ 0.01. Ewgenija Gutjahr contributed to 
Fig. 3.5 B. C. Analysis of microsphere beads phagocytosis using flow cytometry. Cells were either 
untreated or stimulated with 500 ng/ml LPS or 1000 U/ml IFNγ for 24 h (from left to right). LPS 
stimulation increased beads uptake while IFNγ stimulation had no effect. D. Quantification of 
microsphere beads phagocytosis by iPSdM1. Cells were either unstimulated (control) or stimulated 
with 500 ng/ml LPS or 1000 U/ml IFNγ for 24 h. No significant difference in beads phagocytosis 
was observed between control and LPS or IFNγ stimulation. Data are presented as mean ± SEM of 
5 independent experiments. ANOVA post-hoc Bonferroni p-values: n.s.  
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3.1.6 Migratory potential of iPSdM towards fractalkine 
The fractalkine CX3CL1 is one of the major chemokines in the CNS and is mainly 
expressed by neurons. Microglia express the corresponding receptor CX3CR1. 
Using flow cytometry, the expression of the fractalkine receptor CX3CR1 by 
iPSdM was confirmed (Fig. 3.4). Now, the migration of iPSdM towards the 
fractalkine was investigated using a transwell-system (Fig. 3.7).  
IPSdM were attracted through different concentrations of CX3CL1 
(5, 10, 15 and 20 ng/ml). As control, 20 ng/ml of CX3CL1 were added to both the 
lower and the upper chamber of the transwell system to exclude undirected 
migration. Cells that had migrated to the lower chamber and to the backside of the 
membrane were counted and normalized to the migration without CX3CL1 
(0 ng/ml) application (Fig. 3.7). The application of 5 ng/ml fractalkine resulted in a 
slight increase of migrated cells to 16.6 ± 2.3 % in comparison to the control 
(9.4 ± 1.9 %). The usage of 10 ng/ml fractalkine significantly increased the number 
of migrated cells to 28.4 ± 3.4 % (p = 0.020). Treatment with 15 ng/ml CX3CL1 
significantly increased the number of migrated cells to 36.4 ± 2.6 % (p = 0.001) 
and 20 ng/ml CX3CL1 to 29.9 ± 6.0 % (p = 0.011). Interestingly, the fractalkine 
concentration of 20 ng/ml did not further increase the number of migrated cells in 
comparison to 15 ng/ml CX3CL1. In summary, a dose-dependent migration of 
iPSdM towards the fractalkine could be observed. 
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Fig. 3.7: In vitro transwell migration assay of iPSdM1 towards CX3CL1. Microglial precursor 
cells migrated in a dose-dependent manner towards the chemokine CX3CL1. To exclude 
undirected migration, 20 ng/ml CX3CL1 were added to both wells of the transwell system as 
control. Data are presented as mean ± SEM of 3 independent experiments. ANOVA post-hoc 
Bonferroni p-values vs. control: * p ≤ 0.05, *** p ≤ 0.001. Data obtained in cooperation with 
Ewgenija Gutjahr. 
 
3.1.7 Engraftment of iPSdM into the CNS of immunodeficient mice 
To study the engraftment into the CNS, iPSdM were lentivirally transduced with 
GFP. GFP expressing iPSdM were transplanted into the hippocampus (Fig. 3.8 A) 
of Rag2/IL-2R knockout mice lacking B cells, T cells and natural killer cells. Three 
and nine weeks post-transplantation mice were sacrificed, brains were isolated 
and 20 µm cryosections were prepared. Immunohistochemical analysis showed 
that GFP positive cells were detectable in the brain close to the injection area. 
Those GFP positive cells could be stained for the microglial marker CD68 
indicating the microglial phenotype (Fig. 3.8 C). Moreover, GFP-iPSdM were 
localized next to GFAP positive astrocytes. Furthermore, GFP-iPSdM integrated 
into the brain tissue, migrated out of the dentate gyrus and built processes 
(Fig. 3.8 B). The number of GFP-iPSdM integrated into the brain tissue was 
analyzed three and nine weeks post-transplantation (Fig. 3.8 D). After three weeks 
48.4 ± 8.9 cells/mm² and after nine weeks 26.7 ± 11.3 cells/mm² were found in the 
dentate gyrus. Cells were distributed over an area of 0.4 ± 0.1 mm² (3 weeks) and 
0.7 ± 0.1 mm² (9 weeks). Next, the number of GFP positive cells migrated out of 
Results 38 
the dentate gyrus was counted. After 3 weeks 6.3 ± 2.5 % and after nine weeks 
56.3 ± 4.5 % of GFP-iPSdM migrated out of the dentate gyrus. In summary, GFP-
iPSdM could be transplanted into the brain of immunodeficient mice where they 
migrated and integrated into the brain tissue. 
 
 
 
Fig. 3.8: Engraftment of GFP transduced iPSdM1 into the CNS of immunodeficient mice. 
IPSdM1 were lentivirally transduced with GFP and transplanted into the hippocampus of 
immunocompromised Rag2/IL-2R deficient mice. A. Schematical illustration of a frontal mouse 
brain section taken from the mouse brain atlas of Paxinos and Franklin, which shows the 
transplantation area (referred to Bregma: 2.4/1.5/1.4-1.6) of GFP-iPSdM1 into Rag2/IL-2R deficient 
mice. B. Nine weeks post-transplantation mice were sacrificed and cortical tissue sections were 
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analyzed for GFP positive cells. GFP-iPSdM integrated into the brain tissue and buil processes. 
Scale bar: 25 µm. C. Nine weeks post-transplantation mice were sacrificed and cortical tissue 
sections were immunostained with antibodies directed against the microglial marker CD68 and the 
astrocytic marker GFAP. GFP-iPSdM1 engrafted into the brain tissue, were stained for CD68 and 
localized nearby GFAP positive astrocytes. Scale bars: 25 µm. D. Quantification of transplanted 
GFP-iPSdM1 in the dentate gyrus of Rag2/IL-2R deficient mice 3 and 9 weeks post-transplantation. 
No significant difference in GFP positive cells /mm² as well as their distribution in the dentate gyrus 
was observed. However, 9 weeks post-transplantation more cells migrated out of the dentate gyrus 
in comparison to 3 weeks post-transplantation. Data are presented as mean ± SEM. Student’s 
t-test p-values: * p ≤ 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 40 
3.2 iPSdM as a model system for SOD1 mediated      
      amyotrophic lateral sclerosis  
ALS is a neurodegenerative disease characterized by progressive muscle 
weakness, inflammation and microglial activation. In familial ALS, the most 
common causes are mutations in the SOD1 gene. This protein catalyzes the 
conversion of superoxide to hydrogen peroxide. The expression of mSOD1 in 
neurons leads to motor neuron degeneration. Accumulation of mSOD1 in microglia 
does not affect disease onset but the progression of the disease. However, the 
role of mSOD1 in microglia is not fully understood so far. Thus, mSOD1 in 
microglia might have a critical role in exacerbating the disease. However, the 
exact mechanism involved is still unclear.   
 
3.2.1 Transduction of iPSdM with mutant SOD1 
In order to study the role of mSOD1 in human microglia, iPSdM1 were transduced 
with human mSOD1. Three different mutations of SOD1 involved in ALS pathology 
were used: GFP-tagged human SOD1-G37R, -G85R and -G93A. GFP alone and 
wildtype (wt) SOD1 transduced cells served as controls. To verify the expression 
of SOD1, cells were stained with antibodies directed against SOD1. Using 
confocal images and 3D reconstruction SOD1 could be detected inside the GFP 
positive cells throughout the cytoplasm (Fig. 3.9).  
Furthermore, a western blot was carried out to elucidate the expression level of 
mSOD1 in comparison to endogenous SOD1 (Fig. 3.10 A). Endogenous SOD1 
was present in all cell lysates. SOD1-GFP (mSOD1) was detected in iPSdM 
transduced with wt or mutant SOD1 and absent in GFP-iPSdM. The ratio of 
mSOD1 to endogenous SOD1 was calculated (Fig. 3.10 B). Ratio was 
4.9 ± 0.8 fold for iPSdM-SOD1 wt, 11.7 ± 5.9 fold for -SOD1 G37R, 3.9 ± 2.1 fold 
for -SOD1 G85R and 1.6 ± 0.1 fold for -SOD1 G93A. 
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Fig. 3.9: Expression of wildtype and human mutant SOD1 by iPSdM1 detected via 
immunocytochemistry. IPSdM1 were lentivirally transduced with wildtype (wt) or three different 
mutants of GFP-tagged human SOD1 (SOD1 G37R, G85R and G93A). GFP-positive iPSdM1 were 
stained with an antibody directed against SOD1. SOD1 was detected inside GFP-positive cells 
using confocal microscopy and 3D reconstruction. Scale bars: 20 µm.  
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Fig. 3.10: Western blot analysis of the expression of wildtype and human mutant SOD1 by 
iPSdM1. IPSdM1 were lentivirally transduced with wildtype (wt) or three different mutants of GFP-
tagged human SOD1 (SOD1 G37R, G85R and G93A). A. Western Blot analysis of endogenous 
SOD1 (19 kDa) and SOD1-GFP (mSOD1) (50 kDa) which were detected by an HRP-coupled 
secondary antibody in wt and mSOD1 expressing cells. GFP-iPSdM1 were used as control and 
showed a slight band for endogenous SOD1 but no band for GFP-SOD1. Representative western 
blot out of 3 independent experiments. B. Ratio of expressed SOD1-GFP (mSOD1) to endogenous 
SOD1 in wt and mSOD1 expressing iPSdM1. Ratio was 4.9 ± 0.8 fold for iPSdM-SOD1 wt, 
11.7 ± 5.9 fold for -SOD1 G37R, 3.9 ± 2.1 fold for -SOD1 G85R and 1.6 ± 0.1 fold for -SOD1 G93A. 
GFP-iPSdM did not express SOD1-GFP. Data are presented as mean + SEM of 3 independent 
experiments. Data were obtained in cooperation with Dr. Clement, University of Mainz. 
 
3.2.2 Viability and proliferation of mutant SOD1 expressing iPSdM 
Using MTT assay, cell viability of iPSdM expressing GFP, wt or mSOD1 was 
investigated (Fig. 3.11 A). The relative cell viability was normalized to non-
transduced iPSdM which were set as 100 %. No significant difference in cell 
viability was observed between GFP-iPSdM (84.63 ± 2.31 %), iPSdM-SOD1 wt 
(105.49 ± 5.39 %), -SOD1 G37R (97.33 ± 7.24 %), -SOD1 G85R (89.88 ± 5.37 %) 
and -SOD1 G93A (97.93 ± 13.29 %).  
To determine a possible difference in the growth rates between the mSOD1 
expressing iPSdM lines a proliferation assay was performed (Fig. 3.11 B). A 
defined cell number was seeded and cells were counted every 24 h for a total of 
96 h. The mSOD1 expressing iPSdM showed a similar growth behavior among 
each other and in comparison to GFP-iPSdM and non-transduced iPSdM. Non-
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transduced iPSdM had a mean doubling time of 24.6 ± 1.1 h (Fig. 3.3 C). GFP-
iPSdM showed a mean doubling time of 25.2 ± 1.5 h, iPSdM-SOD1 wt of 
25.1 ± 2.5 h, -SOD1 G37R of 24.9 ± 5.2 h, -SOD1 G85R of 24.2 ± 2.2 h and          
-SOD1 G93A of 26.8 ± 2.0 h.  
In summary, transduction of iPSdM with GFP or different mSOD1 changed neither 
cell viability nor growth behavior in comparison to non-transduced cells. 
 
 
 
Fig. 3.11: Cell viability and growth rate of iPSdM1 expressing GFP, wt or mutant SOD1. 
IPSdM1 were lentivirally transduced with wildtype (wt) or different mSOD1. A. Cell viability assay of 
GFP, wt and mSOD1 expressing iPSdM1. Cell viability of mSOD1 expressing iPSdM was detected 
with a MTT assay and compared to iPSdM1 set as 100 %. GFP, wt and mSOD1 expressing 
iPSdM1 showed no difference in cell viability compared to iPSdM. Data are presented as mean 
+ SEM of 3 independent experiments. ANOVA post-hoc Bonferroni p-values vs. iPSdM1: n.s. 
B. Growth rate of GFP, wt and mSOD1 expressing iPSdM1. All lines showed a similar growth rate 
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with a mean doubling time of 25.2 ± 1.5 h for GFP-iPSdM, 25.1 ± 2.5 h for iPSdM-SOD1 wt,            
24.9 ± 5.2 h -SOD1 G37R, 24.2 ± 2.2 h for -SOD1 G85R and 26.8 ± 2.0 h for -SOD1 G93A. Data 
are presented as mean ± SEM of 3 independent experiments. 
 
3.2.2 TNFα transcript levels of mutant SOD1 expressing iPSdM 
Microglia might act neurotoxic through the release of pro-inflammatory cytokines. 
The expression of mSOD1 by microglia could influence the production of pro-
inflammatory cytokines. Therefore, GFP, wt or mSOD1 expressing iPSdM were 
stimulated with LPS, IFNγ or TNFα for 6 h and inducibility of TNFα transcription 
was analyzed via real-time RT-PCR (Fig. 3.12). Untreated cells served as control 
and were set as 1.  
LPS stimulation increased TNFα transcription to 4.7 ± 1.0 fold (p=0.021) in GFP-
iPSdM, 3.0 ± 0.9 fold in iPSdM-SOD1 wt, 4.3 ± 1.5 fold in -SOD1 G37R, 
2.8 ± 0.1 fold (p=0.000) in -SOD1 G85R and 7.4 ± 5.1 fold in -SOD1 G93A.  
IFNγ and TNFα stimulation had no effect on TNFα transcription. IFNγ stimulation 
led to a TNFα transcription of 1.0 ± 0.1 fold in GFP-iPSdM, 1.4 ± 0.2 fold in iPSdM-
SOD1 wt, 1.4 ± 0.4 fold in -SOD1 G37R, 1.1 ± 0.2 fold in -SOD1 G85R and 
1.8 ± 0.7 fold in -SOD1 G93A. TNFα stimulation led to a TNFα transcription of 
1.6 ± 0.8 fold in GFP-iPSdM, 1.1 ± 0.2 fold in iPSdM-SOD1 wt, 1.2 ± 0.4 fold 
in -SOD1 G37R, 0.8 ± 0.1 fold in -SOD1 G85R and 1.1 ± 0.3 fold in -SOD1 G93A.  
No difference in TNFα transcription was observed between GFP-iPSdM and 
iPSdM-SOD1 wt cells. TNFα transcription was not significantly different between 
wt or mSOD1 expressing iPSdM. 
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Fig. 3.12: TNFα gene transcript analysis of iPSdM1 expressing GFP, wt or mutant SOD1. 
TNFα gene transcripts of wt and mSOD1 expressing iPSdM1 lines were analyzed using real-time 
RT-PCR. Cells were either unstimulated (control) or treated with 1000 ng/ml LPS, 1000 U/ml IFNγ 
or 100 ng/ml TNFα for 6 h. No significant differences in the gene transcription of TNFα were 
observed between the GFP-iPSdM and iPSdM expressing SOD1 wt or mutant SOD1. Data are 
presented as mean + SEM of 3 independent experiments. ANOVA post-hoc Bonferroni p-values 
vs. control: * p ≤ 0.05, *** p ≤ 0.001. 
 
3.2.3 Mitochondrial analysis of mutant SOD1 expressing iPSdM 
In mSOD1 expressing cells, the morphology and function of mitochondria can be 
impaired. In this study, mitochondrial activity of complex I (NADH:ubichinone 
reductase), complex IV (cytochrome c oxidase) and citrate synthase were 
investigated (Fig. 3.13). 
No difference in the activity of complex I, complex IV or citrate synthase was 
detected in unstimulated cells. Activities for complex I were 0.016 ± 0.002 U/mg for 
GFP-iPSdM, 0.016 ± 0.004 U/mg for iPSdM-SOD1 wt, 0.019 ± 0.002 U/mg for       
-SOD1 G37R, 0.014 ± 0.002 U/mg for -SOD1 G85R and 0.019 ± 0.003 U/mg for    
-SOD1 G93A expressing iPSdM. Activities for complex IV were 0.356 ± 0.124 
U/mg for GFP-iPSdM, 0.459 ± 0.124 U/mg for iPSdM-SOD1 wt, 
0.525 ± 0.059 U/mg for -SOD1 G37R, 0.467 ± 0.196 U/mg for -SOD1 G85R and 
0.362 ± 0.024 U/mg for -SOD1 G93A expressing iPSdM. Citrate synthase 
activities were 0.410 ± 0.005 U/mg for GFP-iPSdM, 0.385 ± 0.034 U/mg for 
iPSdM-SOD1 wt, 0.382 ± 0.013 U/mg for -SOD1 G37R, 0.360 ± 0.006 U/mg for     
-SOD1 G85R and 0.472 ± 0.101 U/mg for -SOD1 G93A expressing iPSdM. 
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Furthermore, activities of complex I, complex IV and citrate synthase were 
measured in cells stimulated for 24 h with LPS, IFNγ or TNFα. However, no 
differences in enzyme activities for all enzymes were measured for any stimulation 
in comparison to unstimulated cells or in among the different cell lines (data not 
shown). 
 
 
 
Fig. 3.13: Mitochondrial analysis of iPSdM1 expressing GFP, wt or mutant SOD1. Protein 
lysates of iPSdM1 genetically modified with the genes for GFP, SOD1 wt, SOD1 G37R, SOD1 
G85R and SOD1 G93A were analyzed for activity of the mitochondrial respiratory chain enzymes 
complex I, complex IV and citrate synthase. No differences in enzyme activities were observed 
between the iPSdM1 lines expressing GFP, SOD1 wt, SOD1 G37R, SOD1 G85R or SOD1 G93A. 
Data are presented as mean + SEM of 3 independent experiments. ANOVA post-hoc Bonferroni 
p-values: n.s. Data were obtained in cooperation with Prof. Kunz, University of Bonn. 
 
3.2.4 Production of ROS by mutant SOD1 expressing iPSdM 
SOD1 is responsible for the conversion of superoxide to hydrogen peroxide. 
Mutation of SOD1 might lead to an increase in the production and release of ROS. 
Therefore, ROS production of mSOD1 expressing iPSdM in comparison to SOD1 
wt and GFP expressing iPSdM was investigated.  
Dihydroethidium (DHE) reacts with superoxide leading to a bright red colour inside 
the cells depending on the amount of ROS. DHE staining of unstimulated cells 
showed nearly no difference among all lines (Fig. 3.14 A). Stimulation with TNFα 
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for 20 min increased DHE intensity of iPSdM-SOD1 G37R, -SOD1 G85R and        
-SOD1 G93A but not for GFP-iPSdM or iPSdM-SOD1 wt (Fig. 3.14 A).  
Using confocal imaging, DHE intensity was quantified and normalized to 
unstimulated control cells which were set as 1 (Fig. 3.14 B). TNFα stimulation did 
not alter the relative DHE intensity in GFP-iPSdM (1.20 ± 0.18 fold) and in iPSdM-
SOD1 wt (1.05 ± 0.06 fold). In contrast, relative DHE intensity of iPSdM-
SOD1 G37R was significantly increased to 2.30 ± 0.46 fold in comparison to the 
control (+ p=0.006) and to SOD1 wt expressing iPSdM (* p=0.037). In comparison 
to the control, relative DHE intensity was significantly increased to 2.10 ± 0.33 fold 
(+ p=0.000) in iPSdM-SOD1 G85R and to 1.77 ± 0.25 fold (+ p=0.007) in iPSdM-
SOD1 G93A. However, no significant difference in DHE intensity of SOD1-G85R 
and -G93A expressing iPSdM in comparison to wt cells was observed after TNFα 
stimulation. 
Next, cells were stimulated with LPS or IFNγ for 24 h and DHE intensity was 
quantified to the control cells which were set as 1 (Fig. 3.14 C). LPS stimulation 
did not lead to a difference in relative DHE intensity between GFP-iPSdM 
(0.87 ± 0.11 fold), iPSdM-SOD1 wt (1.02 ± 0.08 fold) and -SOD1 G37R 
(0.98 ± 0.09 fold). Relative DHE intensity was increased in iPSdM-SOD1 G85R to 
1.37 ± 0.14 fold. LPS stimulation led to a significant increase in relative DHE 
intensity in iPSdM-SOD1 G93A to 1.51 ± 0.16 fold (* p=0.037) in comparison to wt 
cells.  
IFNγ stimulation did not alter relative DHE intensity of GFP-iPSdM (1.60 ± 0.35), 
iPSdM-SOD1 wt (1.26 ± 0.08 fold), -SOD1 G37R (1.32 ± 0.27 fold) and                  
-SOD1 G85R (1.33 ± 0.10 fold). However, IFNγ stimulation led to a significant 
increase in iPSdM-SOD1 G93A to 2.29 ± 0.27 fold in comparison to the control 
(+ p=0.000) and to SOD1 wt cells (* p=0.007).   
In summary, in comparison to wt cells DHE intensity was significantly increased in 
iPSdM-SOD1 G37R after TNFα stimulation whereas iPSdM-SOD1 G93A react to 
LPS and IFNγ stimulation. 
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Fig 3.14: Reactive oxygen species production by iPSdM1 expressing GFP, wt or mutant 
SOD1. A. Confocal images for detection of reactive oxygen species (ROS) by DHE staining. 
IPSdM1 expressing GFP, wt or mSOD1 were unstimulated (control) or stimulated with 500 ng/ml 
TNFα for 20 min and ROS production was analyzed via DHE staining and confocal images. 
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IPSdM1 expressing SOD1 G37R, SOD1 G85R and SOD1 G93A showed an increased DHE signal 
after TNFα stimulation in comparison to GFP-iPSdM and iPSdM-SOD1 wt. Scale bar: 100 µm. 
B+C. Quantification of DHE intensity after TNFα (B), LPS or IFNγ (C) stimulation. IPSdM1 
expressing GFP, wt or mSOD1 were either untreated (control) or stimulated with 500 ng/ml TNFα 
for 20 min (B), 1000 ng/ml LPS or 1000 U/ml IFNγ for 24 h (C). GFP-iPSdM showed no difference 
in DHE intensity in comparison to SOD1 wt expressing iPSdM. IPSdM1 expressing SOD1 G37R, 
SOD1 G85R and SOD1 G93A showed an increased DHE signal after TNFα stimulation in 
comparison to iPSdM-SOD1 wt and GFP-iPSdM. IPSdM1 expressing SOD1 G93A showed a 
significant increased DHE signal after LPS or IFNγ stimulation in comparison to iPSdM-SOD1 wt. 
Data are presented as mean + SEM of 3 independent experiments. ANOVA post-hoc Bonferroni 
p-values vs. corresponding stimulation of iPSdM-SOD1 wt: * p ≤ 0.05 or vs. control of the same cell 
line: ++ p ≤ 0.01, +++ p ≤ 0.001.   
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3.3 Summary 
The aim of this work was to establish microglial precursor lines derived from 
human induced pluripotent stem cells. In total, four different microglial precursor 
lines (iPSdM) out of 2 different donors have been obtained. Analysis of different 
microglial markers confirmed a strong expression of CD11b, CD11c, CD16/32, 
CD36, CD40, CD45, CD49d, CD86, CD206 and CX3CR1, while expression of the 
stem cell marker CD34 was absent. IPSdM showed characteristic hallmarks of 
microglia such as the inducibility of pro-inflammatory cytokines, phagocytosis and 
migratory capacity. In detail, pro-inflammatory cytokine production of TNFα was 
induced after LPS stimulation. Furthermore, iPSdM phagocytosed Aβ and 
microsphere beads. A dose-dependent migration towards the fractalkine CX3CL1 
by iPSdM was observed. Moreover, iPSdM could be transplanted into the 
hippocampus of immunodeficient mice where they migrated and integrated into the 
brain tissue. Thus, iPSdM showed characteristics of primary microglia. 
Next, iPSdM were used as a model for SOD1-mediated ALS. IPSdM were 
lentivirally transduced to overexpress wt or three different SOD1 mutations (G37R, 
G85R and G93A) and were then investigated. No differences in proliferation and 
cell viability were observed between wt and the different mSOD1 expressing 
iPSdM. LPS, IFNγ or TNFα stimulation did not lead to a significant difference in the 
production of TNFα between SOD1 wt and mSOD1 expressing iPSdM. 
Furthermore, no differences in the activities of the mitochondrial enzymes complex 
I, complex IV and citrate synthase were observed between wt and mSOD1-iPSdM. 
However, ROS production was increased after TNFα stimulation in SOD1 G37R 
and after LPS and IFNγ stimulation in SOD1 G93A expressing iPSdM in 
comparison to iPSdM-SOD1 wt. 
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5 Discussion 
The CNS is regarded as an immune privileged organ as it is shielded around the 
periphery by the blood-brain barrier and the blood-cerebrospinal-barrier. Thereby, 
unlimited entry of blood-derived leukocytes into the CNS can be prevented (Streit, 
2002). Microglia are the only mononuclear phagocytes which represent the 
immune system of the CNS (Ransohoff and Cardona, 2010). Microglia are 
distributed throughout the whole brain and monitor their microenvironment. Upon 
stimuli microglia become activated, migrate to the site of stimuli, clear debris and 
apoptotic cells, promote tissue repair and release soluble neurotrophic factors 
(Streit, 2002; Block et al., 2007). However, pro-inflammatory activated microglia 
can also be neurodestructive through the release of toxic factors like reactive 
oxygen species. It is also reported that microglia are involved in the pathogenesis 
of neurodegenerative diseases (Block and Hong, 2005). Therefore, detailed 
studies about microglial function in the healthy and diseased brain are crucial.  
Primary microglia derived from brains of postnatal mice or rats are often used to 
study microglial function. Primary cells can be obtained by a shaking procedure of 
mixed glial cells (Giulian and Baker,1986). Alternatively, a purified population of 
microglial cells can be obtained using density gradients and flow cytometric sorting 
(Ford et al., 1995). Human microglia can only be obtained in very limited numbers 
from patients undergoing neurosurgery or from post-mortem brains. Recently, a 
new protocol for human microglial isolation was developed (Olah et al., 2011). The 
protocol requires the mechanical dissociation of the brain and density gradient 
purification providing high purity microglia populations. However, the marginal 
availability of human primary microglia complicates biological and functional 
analysis. 
Two different microglial cell lines were developed. One from embryonic brain-
derived macrophages (Janabi et al., 1995) and the other from microglia isolated 
from primary cultures of embryonic human telencephalon (Nagai et al., 2001). 
However, due to the transformation process these cell lines might have an altered 
cytokine profile and are not suitable for therapeutic approaches. Therefore, 
oncogenically transformed cells might not reflect microglial behavior appropriately. 
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In this work, microglial precursors were differentiated from human iPS cells to 
overcome the limitations of insufficient cell numbers and alterations due to 
transduction processes. The generated iPSdM were highly proliferative and could 
be cultivated for 25 passages without losing their properties. Furthermore, the 
differentiation protocol allows the generation of microglial precursors from iPS cells 
derived from patients with neurodegenerative disorders. Thus, this method 
provides the possibility to study microglial characteristics and function in human 
neurodegenerative diseases. 
 
4.1 Generation and characterization of iPSdM 
4.1.1 Generation of iPSdM 
The differentiation procedure was based on a five-step-protocol recently 
developed in our laboratory to generate microglial precursors (ESdM) from mouse 
embryonic stem cells (Napoli et al., 2009; Beutner et al.,2010). Differentiation 
required EB formation followed by neural induction. The protocol is derived from a 
neuroectodermal differentiation protocol leading to the co-development of neurons 
and astrocytes along with microglial precursors. This protocol is based on the 
observation that embryonic stem cell differentiation in culture comprises 
haematopoiesis as found in the yolk sac which give rise to primitive nucleated 
erythroid cells and macrophages (Keller et al., 1993; Inamdar et al., 1997).  
The origin of microglia was under debate for decades including hypotheses from 
mesodermal to neuroectodermal origin (Chan et al., 2007; Takashima et al., 
2007). Fate mapping analysis in mice revealed that embryonic macrophages from 
the yolk sac give rise to microglia (Ginhoux et al., 2010; Ransohoff and Cardona, 
2010). Nearly all adult microglia seemed to arise from these macrophages around 
embryonic day 7.5. 
Therefore, the ESdM develop from a yolk sac intermediate stage and moreover 
get environmental signals from developing neurons and astrocytes. In respect to 
their cell surface markers, ESdM are identical to primitive macrophages derived 
from the yolk sac (Bertrand et al., 2005; Napoli et al., 2009; Beutner et al., 2010). 
A similar developmental program of human microglia can be suggested. 
Differentiation of human embryonic stem cells to EBs models earliest events of 
embryonic hematopoiesis demonstrating yolk sac development and generation of 
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immature CD45 positive macrophages (Zambidis et al., 2005). Therefore, it can be 
presumed that human microglia develop from macrophages in the yolk sac as 
well. 
In this work, two different iPS cell lines from healthy individuals were used to 
generate four microglial precursor lines. Human fibroblasts were reprogrammed to 
iPS cells using a retroviral system with factors known to be involved in self-
renewal and cell proliferation. Indeed, these retroviruses were silenced in iPS cells 
indicating an efficient reprogramming. The obtained iPS cells were similar to 
human ESC (hESC) in respect to their morphology, proliferation, gene expression, 
in vitro differentiation and teratoma formation (Yu et al., 2007). Therefore, iPS cells 
should resemble hESC differentiation and were used for microglial differentiation. 
The differentiation protocol for human microglia from iPS cells was derived from 
the protocol for mouse ESdM differentiation developed in our laboratory (Napoli et 
al., 2009). Since human iPS cells are different from mouse counterparts, the 
mouse protocol had to be adapted to the human system. Both mESC and iPS cells 
were cultivated on irradiated mouse embryonic fibroblasts. While mESC are 
dependent on leukaemia inhibitory factor (Matsuda et al., 1999), the cultivation of 
iPS cells requires FGF2 for self-renewal (Amit et al., 2000). In the study at hand, 
spontaneous differentiation of iPS cells to EBs was induced by removal of self-
renewal signals coming from feeder cells and FGF2. EBs were plated after 8 days 
in culture. At this stage, EBs were positive for nestin as well as CD45 and Iba1, 
indicating the development of neuronal cells and macrophages/microglia. In the 
next step, neural differentiation was induced. Immunostaining revealed CD45 
positive cells within a network of neuronal cells. These findings showed that the 
differentiation procedure led to a mixed culture of neuronal and microglial cells. 
The CD45 positive cells were isolated and enriched in medium supplemented with 
GM-CSF to enhance proliferation. In contrast to mouse ESdM, the obtained 
human microglial lines required a very long time interval up to 4 months for 
maturation of the microglial precursors from the mixed precursor cell population. 
Furthermore, a transient application of the growth factor GM-CSF was essential. 
After some days in culture in medium supplemented with GM-CSF, human 
microglial precursors started to proliferate and build processes. Staining for the 
microglial markers Iba1 and CD68 showed a pure population of microglial 
precursors (iPSdM). Upon isolation, iPSdM could be kept in culture for up to 25 
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passages without changing their morphology. The iPSdM showed an exponential 
growth rate with a mean doubling time of about 26 h. 
 
4.1.2 Phenotype of iPSdM 
Microglial cells share several markers with other immune cells like macrophages. 
However, myeloid cells can be distinguished from each other by a combination of 
phenotypic characterization, location and function (Ransohoff and Cardona, 2010).  
Therefore, iPSdM were investigated in regard to several marker expressions. 
Microglia are described as CD45 and CD11b positive (Guillemin and Brew, 2004). 
CD45 is a transmembrane protein with intrinsic tyrosine phosphatase activity. This 
protein is expressed on nucleated hematopoietic cells and is involved in cellular 
processes like linkage of immunoreceptor signaling with cytokine secretion and 
cell survival. CD11b belongs to the integrin family and together with CD18 forms 
the complement receptor 3 which is involved in phagocyte adhesion, migration and 
ingestion of complement-opsonized particles. Flow cytometry analysis confirmed 
the expression of both CD45 and CD11b on iPSdM hinting towards a microglial 
phenotype. Furthermore, iPSdM expressed CD11c (subunit of the complement 
receptor 4), CD16/32 (Fcγ receptor III and II), CD36 (scavenger receptor B) and 
the fractalkine receptor CX3CL1. The expression of the co-stimulatory molecules 
CD40 and CD86 (B7.2) as well as CD29 and CD49d (members of the integrin 
family) demonstrated their involvement in immunoregulatory functions. It is 
reported that microglia are able to present antigens via MHC class I and II. 
However, under non-activated conditions MHC class II expression is low 
(Peudenier et al., 1991; Benveniste et al., 2001). This is consistent with findings in 
iPSdM which express low levels of MHC class II under unstimulated conditions.  
CD14 can act as associated co-receptor of the toll like receptor (TLR) 4 to 
enhance cell activation via LPS (Viriyakosol et al., 2000). Unstimulated iPSdM did 
not or just slightly express CD14, while it could be upregulated after LPS and IFNγ 
stimulation. This result coincides with data found in primary human microglia 
where unstimulated microglia showed no expression of CD14 while mRNA levels 
of CD14 increased over time after LPS stimulation (Melief et al., 2012).  
Furthermore, iPSdM showed expression of CD206 (mannose receptor) which 
promotes phagocytosis and endocytosis and therefore is thought to be involved in 
innate immunity (Gordon, 2003). A recent publication showed that human primary 
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microglia, in contrast to macrophages, were negative for CD206 (Melief et al., 
2012). The difference to iPSdM might occur due to the different generation 
procedure. Primary human microglia were isolated using density gradient followed 
by magnetic-activated cell sorting. This procedure could lead to a pro-inflammatory 
activation of these cells. High expression of MHC class II protein, which is usually 
induced after activation, indicates that these cells are pro-inflammatory activated 
and therefore CD206 is downregulated. 
The expression of Siglec-11 was observed on iPSdM. Siglecs are immuno-
modulatory receptors which can be divided into two subgroups, the evolutionarily 
highly conserved Siglecs and the CD33-related Siglecs like Siglec-11, which are 
subject to rapid evolutionary changes (Crocker et al., 2007). Siglecs are mainly 
expressed in the hematopoietic and immune system and can mediate cell-cell 
interactions. In the brain, Siglec-11 is exclusively expressed on microglia and 
might be involved in the regulation of innate immune responses (Angata et al., 
2002). 
The iPSdM were generated from pluripotent stem cells, thus the expression of the 
hematopoietic stem cell marker CD34 was investigated. Indeed, CD34 was absent 
on iPSdM lines indicating that iPSdM were fully differentiated. 
In summary, generated iPSdM lines showed a typical marker expression profile 
including CD11b, CD11c, CD16/32, CD45, CD68, CD86 and Iba1 as previously 
described for primary cells and microglia derived from neuropathological stainings 
(Ford et al., 1995; Guillemin and Brew, 2004; Gibbons and Dragunow, 2010; 
Melief et al., 2012). 
 
4.1.3 Functionality of iPSdM 
To further investigate the characteristics of iPSdM, different functional assays 
were performed. 
One typical feature of microglia is the inducibility of pro-inflammatory cytokines 
(Hanisch, 2002). In the study at hand, LPS and IFNγ were used as exogenous or 
endogenous inflammatory triggers to induce TNFα and iNOS gene transcription. 
LPS is a component of the outer membrane of gram-negative bacteria and acts as 
an endotoxin activating the TLR4 whose signaling cascade leads to the production 
of pro-inflammatory cytokines (Viriyakosal et al., 2000). IFNγ is secreted by CD4+ 
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T helper cell type I, CD8+ cytotoxic lymphocytes and natural killer cells. It has 
antiviral, immunoregulatory and anti-tumor properties (Vila-del Sol et al., 2008).  
TNFα is a cytokine that stimulates the acute phase reaction and is involved in 
systemic inflammation. The main function of TNFα is the regulation of immune 
cells. Furthermore, TNFα is described to induce apoptotic cell death and inhibit 
tumorigenesis (Vujanovic, 2011; Montgomery and Bowers, 2012). Macrophages 
are the main producers of TNFα, but microglial activation by LPS or other bacterial 
products results in its production as well (Nakajima and Kohsaka, 1993; Smith et 
al., 2012).  
Real-time RT-PCR data of iPSdM showed the upregulation of TNFα transcript 
levels to 3.3 fold after 6 h of LPS stimulation. The inducibility of TNFα gene 
transcripts after LPS stimulation indicates that LPS acts as immunostimulatory 
substance for iPSdM. Data are in line with literature showing that LPS treatment of 
human fetal microglia led to increased TNFα levels after 2 to 8 h of stimulation, 
while the amount decreased within 24 to 48 h to the basic level (Lee et al., 1993). 
On the other hand, IFNγ did not induce TNFα gene transcription in iPSdM after 6 h 
of stimulation. The induction of cytokine transcripts seems to be dependent on the 
time and type of stimulation. Studies on mouse macrophages showed the 
inducibility of TNFα by IFNγ up to 4 h of stimulation. After 16 h of IFNγ stimulation, 
TNFα levels decreased to their basic level (Vila-del Sol et al., 2008). Using adult 
human microglia, another publication demonstrated increased TNFα transcription 
to about 2.5 fold by IFNγ after 8 h of stimulation (Becher et al., 1996). Data of 
iPSdM showed that IFNγ stimulation had no impact on TNFα gene transcription 
within the first 6 h. Further experiments with different stimulation times would result 
in more information about the ability of iPSdM to react on IFNγ stimulation with 
increased TNFα transcription. As iPSdM are generated in vitro, the obtained 
microglial lines did not receive intrinsic or extrinsic factors, which might be a 
reason for different behavior in response to pro-inflammatory stimulation. For that 
reason iPSdM are defined as microglial precursor cells. 
The enzyme iNOS can be induced by immunostimulatory cytokines, bacterial 
products and other substances (Aktan, 2004; Kleinert et al., 2004). It is 
responsible for the synthesis of NO from arginine. NO is a free radical that can 
react with superoxide to form peroxynitrite thus leading to cell toxicity. Therefore, 
iNOS is involved in immune defence via antimicrobial and antitumoral activities. 
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However, there seemed to be species specific differences in the production of NO. 
While mouse and rat microglia produce high amounts of NO by activated iNOS, 
human microglial NO was almost undetectable (Colton et al., 1996). Hence, 
iPSdM were investigated regarding their ability to induce iNOS gene transcription 
after stimulation. Real-time RT-PCR data of iPSdM showed no upregulation of 
iNOS after LPS or IFNγ stimulation. Furthermore, NO production was not 
increased after LPS and IFNγ stimulation (data not shown). It is unclear why 
human microglia do not produce NO in substantial amounts. But for human 
endothelial cells, it has been shown that iNOS is epigenetically silenced (Chan et 
al., 2005). 
 
Phagocytosis capacity, an important hallmark of microglia, is a highly coordinated 
process mainly regulated by environmental signals. Two main receptor types are 
involved in phagocytosis - the first, like TLRs, recognizes pathogens and the 
second, recognizes apoptotic material (Napoli and Neumann, 2009). Alzheimer’s 
disease is characterized by extracellular amyloid β (Aβ) plaque formation. The 
aggregated form of Aβ is known to activate microglia through different receptors 
including TLRs (Landreth and Reed-Geaghan, 2009; Saijo and Glass, 2011). The 
clearance of Aβ-plaques might be due to microglia-mediated phagocytosis (Napoli 
et al., 2009; Lee and Landreth, 2010).  
Standard in vitro assays to investigate the phagocytosis capacity of microglia 
includes fibrillary Aβ and microsphere beads uptake. The assay system for the 
phagocytosis capacity of iPSdM in respect to Aβ determined that 18 % of 
unstimulated iPSdM were able to phagocytose Aβ. Stimulation with LPS or IFNγ 
significantly increased Aβ uptake by nearly 200 %. Thus, LPS and IFNγ act as 
stimulatory substance to increase Aβ phagocytosis. 
In a second assay, iPSdM were incubated with fluorescent labeled microsphere 
beads and the number of positive cells was determined using flow cytometry. Cells 
were detached from the culture dish using trypsin to remove unspecific bound 
beads on the surface of the cells. Furthermore, only cells with fluorescent signals 
for more than one bead were taken into account. Unstimulated iPSdM showed an 
uptake of 33 % beads. LPS stimulation led to a slight, but not significant increase 
in beads phagocytosis to 40 %, whereas IFNγ stimulation had no impact.  
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The amount of microsphere beads phagocytosed by human iPSdM was 
comparable or even slightly higher compared to mouse ESdM (Beutner et al., 
2010). However, the used concentration and incubation time with beads between 
mouse and human stem cell-derived microglia differed. Since iPSdM were 
incubated with half the concentration of beads and for a shorter time period than 
ESdM, it appears that iPSdM are more potent in phagocytosis of microsphere 
beads. In contrast, phagocytosis of Aβ was reduced in iPSdM compared to both 
unstimulated mouse primary microglia and ESdM which showed an uptake of Aβ 
in the range of 30 to 60 % (Gaikwad et al., 2009; Napoli et al., 2009).   
Differences between the mouse and human system could occur due to differently 
expressed proteins such as Siglecs. Some receptors of the Siglec family including 
Siglec-11 are exclusively expressed in humans without a counterpart in mice, 
while other CD33-related Siglecs show differences in the signaling cascade 
between mice and humans (Crocker et al., 2007). Mouse CD33 can lead to an 
activatory signaling cascade whereas human CD33 exhibits, similar to Siglec-11, 
an inhibitory signaling (Brinkman-Van der Linden et al., 2003; Varki, 2009; Wang 
and Neumann, 2010). Therefore, studies including the involvement of Siglecs are 
not comparable between mice and humans due to species differences and 
different signaling cascades. Genome-wide association studies demonstrated a 
high association of late-onset Alzheimer’s disease in humans with polymorphisms 
in the CD33 gene (Hollingworth et al., 2011; Naj et al., 2011). Thus, iPSdM 
expressing inhibitory Siglecs (Siglec-11; CD33) might better reflect the situation of 
Alzheimer’s disease, where Aβ is not properly cleared. Therefore, iPSdM might 
serve as a novel tool to study the recently described link between late onset 
Alzheimer’s disease and CD33. 
 
The chemokine CX3CL1 (fractalkine) is constitutively expressed by neurons and 
can promote chemotaxis (Re and Przedborski, 2006). Studies with transgenic 
mice encoding GFP under the promoter of the fractalkine receptor demonstrated 
that microglia are the only cell type in the CNS expressing the corresponding 
receptor CX3CR1 (Jung et al., 2000). The signaling via CX3CL1-CX3CR1 seems 
to be important for the neuron-microglia interaction. CX3CR1 knockout mice 
demonstrated higher microglial activity and increased neuronal death in response 
to inflammatory and neurotoxic stimuli (Cardona et al., 2006). 
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Primary mouse microglia were shown to migrate towards fractalkine (Napoli et al., 
2009). Flow cytometry data revealed the expression of CX3CR1 by iPSdM. 
Therefore, a migratory potential of iPSdM towards fractalkine could be expected. 
Using a transwell-system, the number of microglia which migrated towards 
fractalkine was analyzed. The evaluation showed that iPSdM display the capacity 
to migrate towards fractalkine. The number of migrated cells increased by 
approximately three-fold up to a concentration of 15 ng/ml fractalkine in 
comparison to undirected migration. Thus, iPSdM responded to fractalkine in vitro 
with migration in a dose-dependent manner. 
Furthermore, the migration of iPSdM in vivo was analyzed. After intracerebral 
transplantation into immunodeficient mice, iPSdM also showed migration in vivo. 
Transplanted iPSdM developed typical microglial processes and integrated into 
the brain tissue. Since microglial cells might degenerate in the aging brain (Streit 
et al., 2008) or in Alzheimer’s disease (Streit et al., 2009) and the natural source 
(yolk sac derived macrophages) is no longer available, iPSdM could form a novel 
source for a replacement therapy of senescent microglia. 
 
4.2  iPSdM as a model for SOD1-mediated ALS 
ALS is a late-onset neurodegenerative disease mainly affecting motor neurons in 
the brain and spinal cord (Bento-Abreu et al., 2010). Mutations in the Cu/Zn SOD1 
gene are the most common form of inherited ALS, accounting for 20 % of all 
familial ALS forms and corresponding to 1 – 2 % of all ALS cases (Boillee et al., 
2006a). A pathogenic role of microglia in ALS was suggested based on data of the 
SOD1 animal model over-expressing mutant human SOD1 G37R (Boillee et al., 
2006b). Conditional inactivation of mutated SOD1 in CD11b+ microglia extended 
the survival of mice by preventing disease progression, particularly during the late 
phase of disease (Boillee et al., 2006b). Active involvement of microglia in ALS 
was also shown in another study using PU.1-deficient mice which lack 
macrophages, neutrophils, B and T cells and microglia (Beers et al., 2008). These 
mice were crossed to mice expressing the SOD1 G93A gene and then received 
bone marrow transplants from wildtype mice resulting in donor-derived microglia. 
Mice reconstituted with wildtype microglia showed significantly longer survival and 
decreased motor neuron loss, indicating a pathology-promoting role of 
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SOD1 G93A microglial cells. Thus, both approaches indicated that microglia are 
not involved in the onset but in the progression of the disease. However, the exact 
role of microglia in SOD1-mediated ALS is not fully understood. 
 
Apparently, neuroinflammation contributes to motor neuron damage. Increased 
TNFα levels in the brain and spinal cord of mice coincide with the onset of motor 
neuron dysfunction (Strong, 2003). Furthermore, microglial contribution to 
neuronal impairment was demonstrated. The supernatant of LPS stimulated 
microglial cells induced motor neuron cell death through a TNFα-dependent 
pathway (He et al., 2002).  
Therefore, relative TNFα gene transcripts of iPSdM expressing GFP, wt or mutant 
SOD1 after stimulation with LPS, IFNγ or TNFα were investigated. Similar to non-
transduced iPSdM, IFNγ stimulation did not increase TNFα transcript levels in any 
cell line. Additionally, TNFα stimulation neither had an effect in any cell line on 
TNFα transcription resembling data found in human fetal microglia where TNFα 
stimulation did not lead to TNFα cytokine production (Lee et al., 1993). In contrast, 
LPS stimulation increased TNFα transcript levels in comparison to unstimulated 
cells in all cell lines. Contrary to literature, no significant difference in TNFα 
upregulation was observed between GFP or SOD1 wt and mutant SOD1 
expressing iPSdM. But, experiments with adult mice ubiquitously expressing 
human SOD1 G93A demonstrated higher release of TNFα levels by SOD1 G93A-
microglia in comparison to wt cells (Weydt et al., 2004). However, this effect 
seemed to be age-dependent since SOD1 G93A and wt microglia from neonatal 
mice showed similar TNFα levels after LPS stimulation. Since iPSdM are 
generated based on embryonic differentiation, these cells might imitate more fetal 
or embryonic cell behavior. Thus, iPSdM might not reflect age-dependent effects 
of mSOD1 expressing microglia. With age, cells enter into growth arrest termed 
replicative senescence associated with telomere shortening and changes in gene 
expression profile (Chen et al., 2007). It became evident that replicative 
senescence is an example for a more widespread response termed cellular 
senescence, which can be induced by substances that cause DNA damage, 
strong mitogenic signals or disrupt heterochromatin. As in vitro model for aging 
research, oxidative stress is used to induce cellular senescence for example by 
hydrogen peroxide. Thus, this method could provide the opportunity to study age-
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dependent effects on the stimulation of TNFα transcription by mutant SOD1 
expressing iPSdM.   
So far, most knowledge on SOD1-mediated ALS is based on mouse models 
expressing mSOD1. Whether results obtained in mouse are comparable to the 
human system remains to be assessed. In contrast to rodent microglia, human 
microglia do not upregulate NO after pro-inflammatory stimulation (Peterson et al., 
1994). Such species difference has been claimed to be responsible for failure of 
translation of anti-inflammatory therapies from animal models to clinical therapy of 
patients suffering from neurodegenerative diseases (Dragunow, 2008). In addition, 
this diversity could lead to different results when comparing data from the mouse 
and the human system. Thus, iPSdM provide an essential tool to study the 
involvement of human microglia in neurodegenerative diseases. 
 
Mitochondria represent the energy source of the cell being involved in cell 
respiratory processes, apoptosis and free radical production (Filosto et al., 2011). 
Ultrastructural and functional alterations of mitochondria were detected in several 
neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s 
disease and ALS (Filosto et al., 2011). Furthermore, data indicate the involvement 
of mitochondrial damage in motor neuron degeneration in mice expressing 
mSOD1 (Wong et al., 1995; Kong and Xu, 1998). Changes in the electron-
transport chain (ETC) in mitochondria were shown in human spinal cord samples 
of patients with sporadic ALS (Fujita et al., 1996; Borthwick et al., 1999) and brain 
tissue of patients with SOD1-mediated ALS (Bowling et al., 1993; Browne et al., 
1998). However, studies of mitochondrial alterations in ALS in microglia are 
absent.  
In this work at hand, mSOD1 expressing iPSdM were investigated regarding their 
mitochondrial enzyme activities compared to SOD1 wt expressing cells. No 
differences were measured for complex I, IV and citrate synthase activities 
between wt and mSOD1 expressing iPSdM. Results obtained for complex IV are 
in line with data from spinal cord of rats expressing SOD1 G93A (Li et al., 2010) 
and human brain tissue from familial ALS patients (Bowling et al., 1993) showing 
no difference in complex IV activity. In contrast, outcome for complex I is different 
to publications showing affected activity in mSOD1 G93A rodent models (Browne 
et al., 1998; Jung et al., 2002; Li et al., 2010) and human brain tissue from patients 
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with SOD1-mediated ALS (Bowling et al., 1993). However, most studies 
investigated mitochondrial alterations in the whole tissue or concentrated on motor 
neurons alone regardless of other cell types like glial cells. Mitochondria are 
flexible organelles with structural diversity among tissue and species (Mannella, 
2008). Investigations of mouse models for Parkinson’s disease revealed different 
levels of ultrastructural damage in mitochondria of neurons and glial cells (Schmidt 
et al., 2011). Therefore, a diverse vulnerability between neurons and microglia for 
mSOD1 on mitochondria could be likely.   
 
Respiratory burst describes the release of ROS by phagocytes to degrade 
internalized particles and bacteria. The most important ROS are NO, superoxide 
and hydrogen peroxide (H2O2) which are toxic to microbial particles. Previous 
studies suggested a role of oxidative damage in the pathogenesis of ALS and a 
possible link to the expression of mSOD1. Overexpression of different mSOD1 in 
human neuroblastoma cell lines led to increased mitochondrial (Zimmerman et al., 
2007) and cytosolic (Beretta et al., 2003) ROS production. Furthermore, increased 
superoxide levels were detected in the spinal cord and brain of SOD1 G93A 
expressing mice (Harraz et al., 2008). 
In the present study, superoxide production by mSOD1 expressing iPSdM was 
investigated in either unstimulated cells or cells stimulated with TNFα, LPS or 
IFNγ. Among the different cell lines nearly no difference in superoxide production 
was observed in unstimulated cells. But, superoxide production was increased 
after TNFα stimulation in iPSdM-SOD1 G37R in comparison to SOD1 wt cells, but 
no change was detected after LPS or IFNγ treatment. In contrast, iPSdM-
SOD1 G85R showed no difference in superoxide production after any stimulation 
compared to SOD1 wt cells. Differences between the mutations could occur due to 
different dismutase activities of the mSOD1 proteins. Although all three are gain-
of-function mutations, SOD1 G85R shows no difference in SOD1 activity whereas 
SOD1 G37R and SOD1 G93A have 3 – 14 fold increased activity levels (Gurney et 
al., 1994; Wong et al., 1995; Bruijn et al., 1997). Furthermore, studies in mice 
expressing different mSOD1 suggest that SOD1 mutations seem to have specific 
effects on ALS pathogenesis. Knockdown of SOD1 G85R in astrocytes in G85Rflox 
transgenic mice delayed disease onset and duration (Wang et al., 2011), whereas 
loss of astrocytic SOD1 G37R affected only the late phase of the disease 
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(Yamanaka et al., 2008). Different influences of the mutations in disease 
progression suggest diverse effects also in other mechanisms involved in ALS 
pathogenesis such as ROS production. The present study demonstrates an 
increase in superoxide production in iPSdM-SOD1 G93A after LPS or IFNγ but not 
TNFα stimulation compared to SOD1 wt cells. Data are in line with a previous 
publication showing increased superoxide and NO levels after LPS stimulation in 
SOD1 G93A mouse primary microglia in comparison to wt cells (Xiao et al., 2007). 
The NADPH oxidase was suggested as main source of ROS production in 
microglia (Harraz et al., 2008). It is a membrane-bound enzyme complex 
consisting of six subunits and responsible for the reduction of oxygen to 
superoxide (Babior, 2004). NOX2, a subunit of the NADPH oxidase, is regulated 
by the GTPase, Rac1. Under reducing conditions, SOD1 can bind to RAC1, 
thereby inhibiting its GTPase activity leading to NOX2 activation, followed by 
superoxide production and conversion into H2O2 by SOD1 (Harraz et al., 2008). 
Increased H2O2 levels in turn lead to the dissociation of SOD1 from Rac1, 
inhibition of NOX2 and finally reduced superoxide and H2O2 production. However, 
this redox-sensitive uncoupling of SOD1 from Rac1 is defect in mSOD1 
expressing microglia leading to increased superoxide levels in unstimulated cells 
(Harraz et al., 2008). Whether the effect of increased superoxide production by 
iPSdM expressing SOD1 G37R or G93A after TNFα or LPS/IFNγ stimulation is 
mediated via the NADPH oxidase has to be determined. Treatment with apocynin, 
an inhibitor of the NADPH oxidase, or lentiviral knockdown of a subunit of the 
NADPH oxidase like NOX2 could give further insights into the mechanism behind. 
 
To conclude, iPSdM present a novel tool for systems biology and might be suitable 
for drug development to understand and target the microglial pathways involved in 
human neuroinflammatory diseases.  
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